ORIGINAL RESEARCH article

Front. Cell. Neurosci., 01 December 2022

Sec. Non-Neuronal Cells

Volume 16 - 2022 | https://doi.org/10.3389/fncel.2022.947732

Predicted molecules and signaling pathways for regulating seizures in the hippocampus in lithium-pilocarpine induced acute epileptic rats: A proteomics study

  • 1. Ningxia Key Laboratory of Cerebrocranial Diseases, College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, China

  • 2. Ningxia Key Laboratory of Cerebrocranial Diseases, Ningxia Medical University, Yinchuan, China

  • 3. School of Clinical Medicine, Ningxia Medical University, Yinchuan, China

  • 4. Ningxia Key Laboratory of Cerebrocranial Diseases, Department of Neurosurgery, General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan, China

  • 5. College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, China

Article metrics

View details

3

Citations

2,7k

Views

1,1k

Downloads

Abstract

Seizures in rodent models that are induced by lithium-pilocarpine mimic human seizures in a highly isomorphic manner. The hippocampus is a brain region that generates and spreads seizures. In order to understand the early phases of seizure events occurring in the hippocampus, global protein expression levels in the hippocampus on day 1 and day 3 were analyzed in lithium-pilocarpine induced acute epileptic rat models using a tandem mass tag-based proteomic approach. Our results showed that differentially expressed proteins were likely to be enhanced rather than prohibited in modulating seizure activity on days 1 and 3 in lithium-pilocarpine induced seizure rats. The differentially regulated proteins differed on days 1 and 3 in the seizure rats, indicating that different molecules and pathways are involved in seizure events occurring from day 1 to day 3 following lithium-pilocarpine administration. In regard to subcellular distribution, the results suggest that post-seizure cellular function in the hippocampus is possibly regulated in a differential manner on seizure progression. Gene ontology annotation results showed that, on day 1 following lithium-pilocarpine administration, it is likely necessary to regulate macromolecular complex assembly, and cell death, while on day 3, it may be necessary to modulate protein metabolic process, cytoplasm, and protein binding. Protein metabolic process rather than macromolecular complex assembly and cell death were affected on day 3 following lithium-pilocarpine administration. The extracellular matrix, receptors, and the constitution of plasma membranes were altered most strongly in the development of seizure events. In a KEGG pathway enrichment cluster analysis, the signaling pathways identified were relevant to sustained angiogenesis and evading apoptosis, and complement and coagulation cascades. On day 3, pathways relevant to Huntington’s disease, and tumor necrosis factor signaling were most prevalent. These results suggest that seizure events occurring in day 1 modulate macromolecular complex assembly and cell death, and in day 3 modulate biological protein metabolic process. In summary, our study found limited evidence for ongoing seizure events in the hippocampus of lithium-pilocarpine induced animal models; nevertheless, evaluating the global differential expression of proteins and their impacts on bio-function may offer new perspectives for studying epileptogenesis in the future.

Introduction

Epilepsy manifests as repeated transient seizures with longer interictal periods between seizures. The primary goal of epilepsy research is to understand the mechanisms of epileptogenesis and ictogenesis. In epilepsy disorders, the brain tends to generate seizures (Fisher et al., 2005). The pilocarpine-induced animal model is commonly used as an epileptic seizure model that mimics the human disease in a highly isomorphic manner (Turski et al., 1983a,b).

Seizures induced by pilocarpine possibly exert their effects through the muscarinic receptor to cause an imbalance between excitatory and inhibitory transmission (Hamilton et al., 1997; Priel and Albuquerque, 2002). The vital characteristics of the pilocarpine model include rapid induction of acute status epilepticus (SE), the presence of a latent period and spontaneous recurrent seizures (SRSs, chronic phase) (Leite et al., 1990; Cavalheiro et al., 1991), the occurrence of widespread lesions, and seizures that are poorly controlled by antiepileptic drugs (Glien et al., 2002; Chakir et al., 2006; André et al., 2007). In a modification of the pilocarpine model, pilocarpine has also been combined with lithium to achieve a reduction dose and increased sensitivity to pilocarpine for inducing seizures; this model is similar to the pilocarpine model behaviorally, metabolically, electrographically, and neuropathologically (Honchar et al., 1983; Clifford et al., 1987).

After injecting pilocarpine, ictal, and interictal epileptic events are evoked and a clear pattern of theta rhythms is evident in the hippocampus (Turski et al., 1983a,b). Along with seizure event development, electrographic seizures are originated in the hippocampus and are propagated from the hippocampus to the amygdala and neocortex (Turski et al., 1983a,b). However, these hippocampal alterations appear to intensify progressively until 80 days after SE. In view of the important role of the hippocampus in generating and spreading seizures in epilepsy, it is important to understand the mechanisms and molecule alterations during early seizure events in animal models and patients with epilepsy. Biochemical changes reflect critical alterations in integral processes during the development of seizure events, yet they have received limited attention. The proteome studies of the human hippocampus in patients with Alzheimer’s disease (Edgar et al., 1999b; Sultana et al., 2007; Begcevic et al., 2013; Hondius et al., 2016), non-CNS malignancies (Yang et al., 2004), and refractory temporal lobe epilepsy has been reported (Persike et al., 2012, 2018). The proteome studies of epileptic animal models in the chronic phase induced by the kindling and pilocarpine models have also studied (Sadeghi et al., 2021). However, studies of biochemical changes during seizures in the acute phase of epileptic animal models have been quite limited to date.

Given the known role of the hippocampus in seizure development, we examined molecules and signaling pathways that may plausibly regulate seizures in the hippocampus using tandem mass tag (TMT)-labeled quantitative proteomic analysis in a lithium-pilocarpine induced epileptic rat model. Our results show that differentially expressed proteins are likely to be enhanced rather than prohibited in modulating seizures in a lithium-pilocarpine induced rat model. On day 1 following lithium-pilocarpine administration, macromolecular complex assembly, RNA binding, the extracellular regulation, and cell death were mainly regulated in the hippocampus. On day 3 following lithium-pilocarpine administration, protein metabolic process, cytoplasm, and protein binding were generally modulated. Moreover, on day 1 following lithium-pilocarpine administration (compared with controls), the majority of regulated signaling pathways comprised pathways relevant to cancer (regulating sustained angiogenesis and evading apoptosis), and complement and coagulation cascades. On day 3 following lithium-pilocarpine administration (compared with controls), the majority of regulated signaling pathways were as follows: Huntington’s disease, tumor necrosis factor (TNF) signaling, tight junction, and nuclear factor (NF)-kappa B pathways. Our study may offer potential indicators for seizure development in the acute phase in epilepsy. Although our study found limited evidence for ongoing seizure events in the hippocampus of lithium-pilocarpine induced animal models, evaluating the global differential expression of proteins and their impacts on biological function is critical to understanding the features of seizure events and may offer new perspectives for studying epileptogenesis in the future.

Materials and methods

Lithium-pilocarpine induced status epilepticus rat

Epileptic seizure rats (male Sprague Dawley rats; weight, approximately 220 g, n = 3 in each experimental group) were induced by intraperitoneal (IP) injection of lithium (130 mg/kg in 0.9% saline)-pilocarpine hydrochloride (30 mg/kg in 0.9% saline, Sigma), as previously described (with minor modifications) (Wang et al., 2021). In the present study, only those animals whose convulsion activity reached scale IV and scale V activity levels (Racine, 1972) were utilized; convulsions were allowed to last for 30 min. Finally, convulsion activity was terminated using chloral hydrate (400 mg/kg, Damao, Tianjin, China). The mortality of epileptic seizure rat was 10%. In experiment, three animals were divided in control group, three survival epileptic seizure rats were terminated after 1 day; three survival epileptic seizure rats were terminated after 1 day.

Animals were housed with free access to food and water at 25°C for 1 and 3 days after lithium-pilocarpine administration. At the end of the study, the both hippocampus of each rat was collected for TMT-labeled quantitative proteomic analysis (Jingjie, Hangzhou, China). All protocols and procedures were approved by the National Institutes of Health and the ethics committee of Ningxia Medial University (Ningxia, China). We followed all relevant national and international guidelines for animal care and welfare (e.g., the ARRIVE guidelines) in conducting this study. Research involving animals and all protocols and procedures were approved by the National Institutes of Health and the animal welfare committee of Ningxia Medical University (Ethics Approval Number: 2019-151, Ningxia, China).

Tandem mass tag-labeled quantitative proteomic analysis

The hippocampi obtained from epileptic rats from all experimental groups were analyzed by quantitative proteomic analysis. All collected samples were ground into cell powder using liquid nitrogen. Four volumes of lysis buffer (8 M urea, 1% Protease Inhibitor Cocktail) were added and the samples were sonicated three times on ice using a high intensity ultrasonic processor (Scientz, Ningbo, China). The supernatant was collected after centrifugation at 12,000 g at 4°C for 10 min, and protein concentrations were measured using a bicinchoninic acid assay kit according to the manufacturer’s instructions. After that, the supernatant was incubated with trypsin in order to digest the protein to a peptide product. The peptide was desalted using a Strata X C18 SPE column (Phenomenex, Torrance, CA, USA) and was vacuum-dried. The peptide was reconstituted in 0.5 M triethylammonium bicarbonate (TEAB) and labeled with a TMT kit according to the manufacturer’s protocol.

Database search

The MaxQuant search engine (v.1.5.2.81) was used to analyze the resulting tandem mass spectrometry (MS/MS) data, and the Human UniProt Database2 was concatenated with a reverse decoy database search for the tandem mass spectra. Trypsin/P was used as the cleavage enzyme, allowing for up to four missing cleavages. The set of mass tolerance for precursor ions in the first search was 20 ppm; this value was set to 5 ppm in the main search (0.02 da, mass tolerance for fragment ions). Carbamidomethyl on Cys was specified as a fixed modification, whereas acetylation and oxidation on Met were specified as variable modifications. The false discovery rate (FDR) was adjusted to <1% and the minimum score for modified peptides was set at >40.

Gene ontology annotation

The UniProt-GOA database3 was used to perform Gene Ontology (GO) annotation of the proteome. Proteins were classified by Gene Ontology annotation based on three categories: biological processes, cellular components, and molecular function.

Enrichment of gene ontology analysis

A two-tailed Fisher’s exact test was used to test the enrichment of the differentially expressed proteins against all identified proteins in each category of the GO annotation. A corrected p-value of <0.05 was considered statistically significant.

Enrichment of pathway analysis

The Encyclopedia of Genes and Genomes (KEGG) database was used to identify enriched pathways using a two-tailed Fisher’s exact test for enrichment of differentially expressed proteins among all identified proteins. Pathways with a corrected p-value of <0.05 were considered statistically significant. These pathways were classified into hierarchical categories according to criteria applied within the KEGG website.

Statistics

All data were reported as means ± standard errors of the mean (SEM) for the three independent experiments. Statistical analysis was performed with one-way analysis of variance (ANOVA), followed by Benjamini and Hochberg (BH) with FDR correction in code of R followed by a Tukey’s post-test (Jingjie, Hangzhou, China). Two-tailed Fisher’s exact tests were used to calculate the statistical significance of the values of the conditions in each comparison for each independent condition in GO analysis (UniProt-GOA database, see footnote 3, and the InterProScan soft) and KEGG (KEGG Orthology database, and KAAS). In all cases, the threshold for statistical significance was set at p < 0.05.

Results

Identification of differentially expressed proteins in the hippocampus

As shown in Figure 1, proteins in the hippocampus were analyzed in three biological replicates. To understand the early phase of seizure events occurring in the hippocampus, global protein expression levels in the hippocampus on day 1 and day 3 in lithium-pilocarpine induced acute epileptic rat models were analyzed using a TMT-based proteomic approach. In total, 6,157 proteins were identified, and 5,593 proteins were quantified. Therefore, the fold-change threshold was set to 1.2, and statistically significant values were defined as those with corrected p-values of <0.05.

FIGURE 1

On day 1 following lithium-pilocarpine administration, the expression of 89 proteins was upregulated, whereas the expression of 28 proteins was downregulated compared with controls (Table 1). On day 3 following lithium-pilocarpine administration, the expression of 34 proteins was promoted whereas that of 25 proteins was inhibited as compared with controls (Table 2).

TABLE 1

Protein accessionProtein descriptionGene nameMean ± SEM
(Day 1)
Mean ± SEM
(Day 3)
Mean ± SEM
(ctrl)
P-value
(Day 1/Day 3/ctrl)
P-value
(Day 1/ctrl)
A0A096MJE3G1 to S phase transition 2Gspt21.13 ± 0.0730.946 ± 0.0150.93 ± 0.1040.0371137030.044872317
A0A0A0MXY7Uncharacterized protein1.16 ± 0.0311.038 ± 0.1990.799 ± 0.0420.0257767790.023109735
A0A0A0MY39ATP-binding cassette sub-family B member 9Abcb91.246 ± 0.160.922 ± 0.0420.839 ± 0.0710.0047604010.004728188
A0A0G2JY31Alpha-1-antiproteinaseSerpina11.395 ± 0.3240.868 ± 0.0850.735 ± 0.0480.0045972870.004442122
A0A0G2JYD1Ubiquitin-associated protein 2Ubap21.082 ± 0.0511.068 ± 0.0610.854 ± 0.0450.0025243320.003693646
A0A0G2K2E2Antizyme inhibitor 2Azin21.092 ± 0.1541.111 ± 0.0180.804 ± 0.1250.0266245220.046602584
A0A0G2K5J5Netrin G2Ntng21.165 ± 0.130.991 ± 0.0840.844 ± 0.0570.0133490570.010926122
A0A0G2K5T6RNA polymerase I and III subunit CPolr1c1.159 ± 0.0551.003 ± 0.1350.837 ± 0.0290.0109437220.008969521
A0A0G2K624Brain-derived neurotrophic factorBdnf1.143 ± 0.1511.08 ± 0.0680.778 ± 0.0890.0082416530.009860647
A0A0G2K7W6Similar to 60S ribosomal protein L27aRGD15624021.075 ± 0.0871.045 ± 0.1270.838 ± 0.0590.0353768460.041811288
A0A0G2K9J8LisH domain-containing protein ARMC9Armc91.108 ± 0.1631.033 ± 0.0350.853 ± 0.0610.0417362270.04131062
A0A0G2QC03Influenza virus NS1A-binding proteinIvns1abp1.123 ± 0.071.016 ± 0.0760.861 ± 0.130.0433823640.038141301
A0A0H2UHH940S ribosomal protein S24Rps241.089 ± 0.0391.068 ± 0.0940.837 ± 0.1130.0273336210.035307812
A0A0H2UHI5Serine protease inhibitorSerpina3n1.592 ± 0.2680.795 ± 0.2230.607 ± 0.0660.0023216110.002250448
A0A0H2UHP9RCG39700, isoform CRA_dRab6a1.158 ± 0.0650.964 ± 0.0670.881 ± 0.0520.0045237620.004012812
B1WBR8F-box and leucine-rich repeat protein 4Fbxl41.601 ± 0.1040.684 ± 0.040.703 ± 0.0490.00000580.0000113
B1WC40Nuclear cap-binding protein subunit 2Ncbp21.123 ± 0.0150.947 ± 0.0480.934 ± 0.0390.0019776010.002786505
B2GV14Taxilin alpha OS = Rattus norvegicusTxlna1.112 ± 0.0380.987 ± 0.050.903 ± 0.0670.010158740.008415176
B2RYK22-(3-amino-3-carboxypropyl)histidine synthase subunit 1Dph11.127 ± 0.1230.978 ± 0.0570.895 ± 0.0480.033088070.028558263
B2RYW7RCG26543, isoform CRA_bSrp141.118 ± 0.1210.973 ± 0.0980.883 ± 0.0250.0460597450.039736226
D3ZB76DnaJ (Hsp40) homolog, subfamily B, member 5 (Predicted)Dnajb51.135 ± 0.0880.994 ± 0.0270.875 ± 0.0120.0017044280.001359745
D3ZBL6Nucleoporin 160Nup1601.123 ± 0.1071.071 ± 0.1350.805 ± 0.1150.0342141320.039021308
D3ZGR7RCG51149Trir1.185 ± 0.0870.886 ± 0.0480.932 ± 0.0920.0085746150.022044093
D3ZHV3MetallothioneinMt1m1.378 ± 0.2061.092 ± 0.4330.47 ± 0.0320.0090315720.008623115
D3ZML3Cyclin-dependent kinase 11BCdk11b1.119 ± 0.0560.979 ± 0.050.91 ± 0.0280.0039175020.003392973
D3ZMQ0MGA, MAX dimerization proteinMga1.125 ± 0.1080.964 ± 0.0290.919 ± 0.0460.0211655790.021150701
D3ZR12Syntrophin, gamma 2Sntg21.097 ± 0.0871.068 ± 0.0810.834 ± 0.0930.0180113490.022843965
D3ZWS6N(alpha)-acetyltransferase 30, NatC catalytic subunitNaa301.08 ± 0.0381.057 ± 0.0790.862 ± 0.0290.0032763910.004270506
D3ZXL5Nuclear cap-binding subunit 3Ncbp31.124 ± 0.1711.033 ± 0.1070.848 ± 0.0360.0487546090.045718377
D3ZYS7G3BP stress granule assembly factor 1G3bp11.082 ± 0.0371.002 ± 0.0520.896 ± 0.0480.008056890.006715078
D4A017Transmembrane protein 87ATmem87a1.13 ± 0.1010.985 ± 0.1120.883 ± 0.0420.038235880.032409648
D4A0W1ER membrane protein complex subunit 4Emc41.13 ± 0.050.903 ± 0.1150.911 ± 0.0680.029950420.049835285
D4A1U7Round spermatid basic protein 1Rsbn11.737 ± 0.1040.621 ± 0.0370.627 ± 0.0480.00000180.0000031
D4A563Pseudopodium-enriched atypical kinase 1Peak11.065 ± 0.1231.035 ± 0.0270.875 ± 0.0410.0360898690.04251408
F1LP80Neurosecretory protein VGFVgf1.266 ± 0.11.041 ± 0.140.691 ± 0.0420.0008455720.000742592
F1LR84Neuronal pentraxin-2Nptx21.134 ± 0.0931.183 ± 0.3740.687 ± 0.0310.0319458840.049143426
F1LST1FibronectinFn11.408 ± 0.0310.861 ± 0.0190.721 ± 0.0170.00000010.0000001
F1LTU4Ribosome assembly factor mrt4Mrto41.175 ± 0.080.911 ± 0.1260.911 ± 0.0480.0211223680.033445134
F1LZW6Solute carrier family 25 member 13Slc25a131.176 ± 0.1030.897 ± 0.0520.94 ± 0.0180.0039322350.011410437
F1M0A0AnoctaminAno31.18 ± 0.1590.997 ± 0.1250.826 ± 0.1150.0487906390.041219969
F7EUK4Kininogen-1Kng11.535 ± 0.1021.012 ± 0.4240.44 ± 0.1120.0041426260.003524826
G3V6S8Serine/arginine-rich splicing factor 6Srsf61.079 ± 0.0381.024 ± 0.0510.898 ± 0.0450.0063409980.005933366
G3V7342,4-dienoyl CoA reductase 1, mitochondrial, isoform CRA_aDecr11.081 ± 0.0531.026 ± 0.0640.896 ± 0.0240.0080053580.007554546
G3V7K3CeruloplasminCp1.232 ± 0.1890.981 ± 0.2350.799 ± 0.0230.0563006250.048127174
G3V8D0ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3St8sia31.06 ± 0.0681.089 ± 0.0640.858 ± 0.0710.0100777930.021673603
G3V9W2Tyrosine-protein kinaseJak11.072 ± 0.0471.043 ± 0.0640.885 ± 0.0560.0130130080.015147659
M0R965Uncharacterized proteinLOC6850251.265 ± 0.2030.902 ± 0.0810.837 ± 0.0460.0078749340.008723589
O35532Methylsterol monooxygenase 1Msmo11.117 ± 0.0460.982 ± 0.0830.906 ± 0.0360.0129413430.011098348
O35547Long-chain-fatty-acid–CoA ligase 4Acsl41.108 ± 0.0780.987 ± 0.0470.919 ± 0.0280.0139007160.011886134
O35760Isopentenyl-diphosphate Delta-isomerase 1Idi11.104 ± 0.0081.006 ± 0.0740.912 ± 0.0830.0376231310.031500687
O35821Myb-binding protein 1AMybbp1a1.135 ± 0.070.994 ± 0.0460.894 ± 0.0470.0051120570.004164782
P01048T-kininogen 1Map11.385 ± 0.3811.059 ± 0.5890.538 ± 0.0790.0431082940.037977515
P02680Fibrinogen gamma chainFgg1.561 ± 0.3030.786 ± 0.030.648 ± 0.0670.0003358280.00034631
P02803Metallothionein-1Mt11.531 ± 0.1340.905 ± 0.2360.543 ± 0.0690.0014703080.001174416
P04961Proliferating cell nuclear antigenPcna1.232 ± 0.1810.965 ± 0.1610.779 ± 0.0340.0184474440.015287816
P05943Protein S100-A10S100a101.637 ± 0.4730.698 ± 0.1440.645 ± 0.1860.0080898120.010515729
P06238Alpha-2-macroglobulinA2m1.361 ± 0.0470.962 ± 0.1470.666 ± 0.0740.0007929120.000628868
P06762Heme oxygenase 1Hmox11.687 ± 0.6220.826 ± 0.1070.491 ± 0.060.0019630840.001591598
P14480Fibrinogen beta chainFgb1.598 ± 0.3640.758 ± 0.0210.66 ± 0.0460.0005297150.000620191
P16975SPARCSparc1.08 ± 0.0571.053 ± 0.1180.874 ± 0.0330.0256904820.030097449
P20059HemopexinHpx1.409 ± 0.1310.867 ± 0.120.708 ± 0.0410.0003975380.000368949
P30713Glutathione S-transferase theta-2Gstt21.146 ± 0.1150.982 ± 0.0260.875 ± 0.0670.0122062290.010099762
P35355Prostaglandin G/H synthase 2Ptgs21.493 ± 0.5430.985 ± 0.2130.526 ± 0.0710.0067107570.00566147
P52631Signal transducer and activator of transcription 3Stat31.085 ± 0.071.065 ± 0.1720.815 ± 0.0090.0304203010.03815129
P59895Serine/threonine-protein kinase Nek6Nek61.179 ± 0.1660.939 ± 0.1020.887 ± 0.0560.0440209970.046634981
P6131460S ribosomal protein L15Rpl151.124 ± 0.0581.076 ± 0.1810.814 ± 0.0950.0399511660.044296005
P6291260S ribosomal protein L32Rpl321.087 ± 0.0561.034 ± 0.1070.875 ± 0.0470.028430890.028255172
Q02765Cathepsin SCtss1.262 ± 0.0970.884 ± 0.1310.855 ± 0.1620.0275586510.034687309
Q3B8N7TSC22 domain family protein 4Tsc22d41.142 ± 0.1271.005 ± 0.1170.852 ± 0.0590.0360704820.030436262
Q3KR94VitronectinVtn1.281 ± 0.2010.832 ± 0.0450.885 ± 0.0740.0068816870.016683615
Q3T1J1Eukaryotic translation initiation factor 5A-1Eif5a1.288 ± 0.2030.781 ± 0.0690.952 ± 0.0530.0047865770.041311914
Q4FZZ3Glutathione S-transferase alpha-5Gsta51.898 ± 0.1240.571 ± 0.0470.51 ± 0.0340.00000090.0000014
Q4KM45UPF0687 protein C20orf27 homolog1.086 ± 0.0771.035 ± 0.0920.864 ± 0.0250.0150086250.015455778
Q5HZA2Sprouty RTK-signaling antagonist 2Spry21.103 ± 0.1171.059 ± 0.0740.845 ± 0.0790.0255699120.029512024
Q5PPG2LegumainLgmn1.091 ± 0.0741.091 ± 0.2010.794 ± 0.0540.0358606330.049602943
Q5PPG5Chga proteinChga1.208 ± 0.0620.948 ± 0.0790.845 ± 0.0610.0021559170.001929208
Q5U3Y8Transcription factor BTF3Btf31.108 ± 0.0470.986 ± 0.0430.91 ± 0.010.0015144940.001244569
Q5XI28Ribonucleoprotein PTB-binding 1Raver11.114 ± 0.0881.022 ± 0.0920.87 ± 0.0950.041982810.037441659
Q63041Alpha-1-macroglobulinA1m1.162 ± 0.1861.009 ± 0.0670.86 ± 0.0730.0550490970.046839218
Q66HA8Heat shock protein 105 kDaHsph11.087 ± 0.0311.027 ± 0.0890.885 ± 0.0190.009002240.008450019
Q68FY4Group specific componentGc1.316 ± 0.2560.857 ± 0.0140.833 ± 0.0270.0042325810.005987128
Q6P734Plasma protease C1 inhibitorSerping11.229 ± 0.0271 ± 0.1690.771 ± 0.0260.0032619210.002631873
Q6QI89Mortality factor 4-like protein 2Morf4l21.175 ± 0.1351.017 ± 0.0160.813 ± 0.0580.0034107560.002867195
Q71UF4Histone-binding protein RBBP7Rbbp71.109 ± 0.1040.969 ± 0.0380.905 ± 0.0250.0164245340.014568544
Q7TQ70Ac1873Fga1.558 ± 0.3160.767 ± 0.0560.679 ± 0.0720.0006875670.000821385
Q9EPX0Heat shock protein beta-8Hspb81.167 ± 0.0611.009 ± 0.1090.826 ± 0.0120.003110310.002534785
Q9EST6Acidic leucine-rich nuclear phosphoprotein 32 family member BAnp32b1.124 ± 0.0540.959 ± 0.0520.924 ± 0.0420.0059666980.006510222
Q9QZK5Serine protease HTRA1Htra11.39 ± 0.4850.916 ± 0.0890.715 ± 0.0120.022516020.01927177
Q9WVJ6Tissue-type transglutaminaseTgm21.204 ± 0.060.982 ± 0.1720.826 ± 0.0150.0139102870.011555675
A0A0G2JX25GMP reductaseGmpr20.889 ± 0.1060.987 ± 0.0561.118 ± 0.0470.0355146470.02978354
A0A0G2K654Histone cluster 1 H1 family member cHist1h1c0.749 ± 0.0851.017 ± 0.0961.254 ± 0.210.007921440.006647937
A0A0G2K946SPARC/osteonectin, cwcv and kazal-like domains proteoglycan 2Spock20.924 ± 0.0420.979 ± 0.0131.114 ± 0.0320.0010524580.000947972
A0A0G2KA11Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2Prex20.855 ± 0.0711.005 ± 0.0931.111 ± 0.0790.0225753110.019371419
A0A0H2UHF5ATP-sensitive inward rectifier potassium channel 10Kcnj100.766 ± 0.010.985 ± 0.2371.211 ± 0.130.0277078890.023028924
A0A1W2Q674ClaudinCldn100.889 ± 0.0571.014 ± 0.0171.104 ± 0.0840.0119838290.010179599
B2RYI0WD repeat-containing protein 91Wdr910.899 ± 0.0451.027 ± 0.0231.084 ± 0.0120.0010551910.000976489
B5DF45TNF receptor-associated factor 6Traf60.928 ± 0.0560.963 ± 0.0541.119 ± 0.0580.0138046420.01466275
D3ZA21Pleckstrin homology and RhoGEF domain-containing G3Plekhg30.881 ± 0.1291.002 ± 0.0481.128 ± 0.0210.033156670.027745196
D3ZBN0Histone H1.5Hist1h1b0.86 ± 0.0760.985 ± 0.0561.17 ± 0.1680.0351675780.029578354
D3ZCB9Family with sequence similarity 92, member BFam92b0.913 ± 0.0521.022 ± 0.0411.112 ± 0.0720.0134096590.011172678
D3ZIF0Zinc finger protein 512Zfp5120.688 ± 0.0491.112 ± 0.3311.208 ± 0.2190.0460577720.048803418
D3ZXL9Potassium channel tetramerization domain-containing 4Kctd40.931 ± 0.0870.903 ± 0.0321.172 ± 0.0260.0027453780.006217505
D3ZYJ5GRAM domain-containing 1BGramd1b0.943 ± 0.0570.933 ± 0.0871.136 ± 0.040.0173158290.030984495
F1LPX0Mitochondrial intermediate peptidaseMipep0.904 ± 0.010.992 ± 0.0261.118 ± 0.0380.0001605030.000128185
F1LU97SAM and SH3 domain-containing 1Sash10.852 ± 0.0640.989 ± 0.0951.167 ± 0.1580.0318219820.026564789
F1LX28Acyl-CoA thioesterase 11Acot110.938 ± 0.0620.917 ± 0.1131.16 ± 0.0290.0244266380.047601114
F1M695YjeF N-terminal domain-containing 3Yjefn30.912 ± 0.0410.988 ± 0.0481.108 ± 0.040.0046149640.003820617
F1M8H7Actin-associated protein FAM107AFam107a0.768 ± 0.0571.146 ± 0.0231.079 ± 0.0260.00007720.000236951
G3V714Neuroendocrine protein 7B2Scg50.937 ± 0.0520.982 ± 0.0421.139 ± 0.0740.0116701510.011575582
G3V7Z4Glia-derived nexinSerpine20.812 ± 0.0441.124 ± 0.0771.09 ± 0.0640.0011050920.002519461
P08050Gap junction alpha-1 proteinGja10.945 ± 0.060.898 ± 0.0331.183 ± 0.080.002514460.007650803
P43278Histone H1.0H1f00.794 ± 0.0431.039 ± 0.2481.201 ± 0.120.0419641030.036372871
P62804Histone H4Hist1h4b0.835 ± 0.0531.053 ± 0.1361.112 ± 0.1080.0313346730.032976035
Q4KLZ1Transmembrane protein 186Tmem1860.917 ± 0.0530.96 ± 0.0961.133 ± 0.0060.019494870.020474501
Q5XI90Dynein light chain Tctex-type 3Dynlt30.786 ± 0.1710.844 ± 0.1951.387 ± 0.1450.0240118070.029094976
Q63357Unconventional myosin-IdMyo1d0.909 ± 0.0621 ± 0.0731.108 ± 0.0870.0425868770.035800118
Q9Z122Acyl-CoA 6-desaturaseFads20.791 ± 0.0231.118 ± 0.1291.106 ± 0.0260.0014494120.002601096

Differentially expression proteins on Day 1 comparing with control (ctrl) in hippocampus post ANOVA analysis.

TABLE 2

Protein accessionProtein descriptionGene nameMean ± SEM
(Day 1)
Mean ± SEM
(Day 3)
Mean ± SEM
(ctrl)
P-value
(Day 1/Day 3/ctrl)
P-value
(Day 3/ctrl)
A0A0G2JWD6AP-3 complex subunit betaAp3b11.045 ± 0.0221.076 ± 0.0970.881 ± 0.0820.0375655630.04375288
A0A0G2JYD1Ubiquitin-associated protein 2Ubap21.082 ± 0.0511.068 ± 0.0610.854 ± 0.0450.0025243320.00490896
A0A0G2K1W1RAB11 family-interacting protein 5Rab11fip51.054 ± 0.0511.072 ± 0.0660.885 ± 0.0910.0365431690.04601017
A0A0G2K2E2Antizyme inhibitor 2Azin21.092 ± 0.1541.111 ± 0.0180.804 ± 0.1250.0266245220.0349248
A0A0G2K624Brain-derived neurotrophic factorBdnf1.143 ± 0.1511.08 ± 0.0680.778 ± 0.0890.0082416530.01924202
A0A0G2K890EzrinEzr0.988 ± 0.0661.147 ± 0.1970.853 ± 0.0290.0492777470.04156111
A0A0H2UHH940S ribosomal protein S24Rps241.089 ± 0.0391.068 ± 0.0940.837 ± 0.1130.0273336210.04861763
B1WBV1Axin interactor, dorsalization-associatedAida0.995 ± 0.0671.117 ± 0.090.891 ± 0.0640.0271387020.02254102
D3ZB30Polypyrimidine tract binding protein 1, isoform CRA_cPtbp11.029 ± 0.1171.087 ± 0.0490.893 ± 0.0190.0385451740.03592311
D3ZDM7D-aspartate oxidaseDdo0.99 ± 0.0751.108 ± 0.0690.908 ± 0.080.0487417590.04155139
D3ZHV3MetallothioneinMt1m1.378 ± 0.2061.092 ± 0.4330.47 ± 0.0320.0090315720.03498570
D3ZR12Syntrophin, gamma 2Sntg21.097 ± 0.0871.068 ± 0.0810.834 ± 0.0930.0180113490.03484456
D3ZWS6N(alpha)-acetyltransferase 30, NatC catalytic subunitNaa301.08 ± 0.0381.057 ± 0.0790.862 ± 0.0290.0032763910.00730703
D4A8F2Ras suppressor protein 1Rsu10.99 ± 0.0531.117 ± 0.1070.9 ± 0.0820.0519942850.04422024
F1LP80Neurosecretory protein VGFVgf1.266 ± 0.11.041 ± 0.140.691 ± 0.0420.0008455720.0060229
F1LQ22Unconventional SNARE in the ER 1Use11.046 ± 0.0541.082 ± 0.0720.871 ± 0.1090.0402266760.04558807
F1LR84Neuronal pentraxin-2Nptx21.134 ± 0.0931.183 ± 0.3740.687 ± 0.0310.0319458840.04578122
F1LS29Calpain-1 catalytic subunitCapn10.999 ± 0.0831.103 ± 0.060.902 ± 0.0640.0351581380.02937753
F1LVR8Myocardin-related transcription factor AMrtfa1.045 ± 0.1141.076 ± 0.0330.885 ± 0.0370.0325010380.03582711
F7EUK4Kininogen-1Kng11.535 ± 0.1021.012 ± 0.4240.44 ± 0.1120.0041426260.03027817
G3V8D0ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3St8sia31.06 ± 0.0681.089 ± 0.0640.858 ± 0.0710.0100777930.01250406
M0RC17Cell adhesion molecule L1-likeChl10.98 ± 0.0361.115 ± 0.1120.914 ± 0.0660.0459547760.04065344
O35263Platelet-activating factor acetylhydrolase IB subunit gammaPafah1b31.003 ± 0.0721.135 ± 0.1410.886 ± 0.0490.0389260180.03261374
O35314Secretogranin-1Chgb1.022 ± 0.021.093 ± 0.1160.88 ± 0.0430.0217034010.02019491
P02803Metallothionein-1Mt11.531 ± 0.1340.905 ± 0.2360.543 ± 0.0690.0014703080.04114526
P06238Alpha-2-macroglobulinA2m1.361 ± 0.0470.962 ± 0.1470.666 ± 0.0740.0007929120.01891073
P35355Prostaglandin G/H synthase 2Ptgs21.493 ± 0.5430.985 ± 0.2130.526 ± 0.0710.0067107570.04898848
P55063Heat shock 70 kDa protein 1-likeHspa1l0.807 ± 0.1041.472 ± 0.4860.731 ± 0.0820.0244501670.02812714
Q4W1H3Myosin 9bMyo9b0.982 ± 0.141.124 ± 0.0460.895 ± 0.0480.0525094870.04591866
Q5XI44X-ray repair complementing defective repair in Chinese hamster cells 4Xrcc41.026 ± 0.0271.085 ± 0.0470.893 ± 0.0490.0040509630.003805
Q6P734Plasma protease C1 inhibitorSerping11.229 ± 0.0271 ± 0.1690.771 ± 0.0260.0032619210.04450734
Q6QI89Mortality factor 4-like protein 2Morf4l21.175 ± 0.1351.017 ± 0.0160.813 ± 0.0580.0034107560.02788628
Q925D4Transmembrane protein 176BTmem176b1.05 ± 0.2051.242 ± 0.2170.714 ± 0.1880.0451131570.04199842
Q9EPX0Heat shock protein beta-8Hspb81.167 ± 0.0611.009 ± 0.1090.826 ± 0.0120.003110310.03531399
A0A0G2JZ56Ankyrin 2Ank20.966 ± 0.0550.922 ± 0.0481.126 ± 0.0550.0085298570.00860688
A0A0G2K1N9Selenoprotein OSelenoo1.048 ± 0.0650.868 ± 0.0771.093 ± 0.0770.0189825760.02072012
A0A0G2K2R0Uncharacterized protein0.991 ± 0.0470.897 ± 0.0531.123 ± 0.0460.0040799030.00331745
A0A0G2K3 × 6Uncharacterized protein1.014 ± 0.0710.857 ± 0.1181.141 ± 0.0970.0368296530.03157403
A0A0G2K6H2Maleylacetoacetate isomeraseGstz11.013 ± 0.1250.808 ± 0.1071.146 ± 0.120.0312480490.02763363
A0A0G2QC22PAXX, non-homologous end joining factorPaxx0.973 ± 0.0740.904 ± 0.0431.14 ± 0.0970.0201308030.01832119
D3ZBN4Ergosterol biosynthesis 28 homologErg281.058 ± 0.1230.863 ± 0.0681.094 ± 0.0780.0379576540.04283949
D3ZXL9Potassium channel tetramerization domain-containing 4Kctd40.931 ± 0.0870.903 ± 0.0321.172 ± 0.0260.0027453780.00357546
D3ZYJ5GRAM domain-containing 1BGramd1b0.943 ± 0.0570.933 ± 0.0871.136 ± 0.040.0173158290.02337596
D3ZZN3Acetyl-coenzyme A synthetaseAcss11.014 ± 0.1010.899 ± 0.0681.094 ± 0.0490.0532596680.04616768
D4A7T8Family with sequence similarity 81, member AFam81a1.005 ± 0.040.885 ± 0.0761.104 ± 0.110.0411930210.03527131
F1LV07Dynein, axonemal, heavy chain 9Dnah90.973 ± 0.0450.916 ± 0.0671.122 ± 0.0860.0252053290.0232872
F1LX28Acyl-CoA thioesterase 11Acot110.938 ± 0.0620.917 ± 0.1131.16 ± 0.0290.0244266380.02991072
G3V7R4Forkhead box protein O1Foxo10.969 ± 0.0860.906 ± 0.071.136 ± 0.1010.0445947820.0417731
G3V8F9Alpha-methylacyl-CoA racemaseAmacr1.096 ± 0.0530.867 ± 0.0541.048 ± 0.0910.0125440790.03458151
P08050Gap junction alpha-1 proteinGja10.945 ± 0.060.898 ± 0.0331.183 ± 0.080.002514460.0027876
P11530DystrophinDmd1.006 ± 0.0890.875 ± 0.0751.098 ± 0.0430.0257876820.02212798
P18484AP-2 complex subunit alpha-2Ap2a20.976 ± 0.0350.888 ± 0.0431.072 ± 0.0690.0111741050.00911871
P29534Vascular cell adhesion protein 1Vcam11.013 ± 0.0360.891 ± 0.0881.071 ± 0.0190.0225407280.02094853
P60825Cold-inducible RNA-binding proteinCirbp1.006 ± 0.0150.916 ± 0.0541.113 ± 0.0880.0179957560.01481907
Q01984Histamine N-methyltransferaseHnmt1.009 ± 0.0910.822 ± 0.0891.181 ± 0.0010.004503680.00367635
Q3V5 × 8Endonuclease GEndog0.962 ± 0.0220.921 ± 0.0931.128 ± 0.0770.028168490.02842668
Q499N5Acyl-CoA synthetase family member 2, mitochondrialAcsf21.011 ± 0.0340.888 ± 0.0891.1 ± 0.0430.0171281510.01461175
Q5XI90Dynein light chain Tctex-type 3Dynlt30.786 ± 0.1710.844 ± 0.1951.387 ± 0.1450.0240118070.04765999
Q9EP88Brain mitochondrial carrier protein BMCP1Slc25a140.986 ± 0.0850.898 ± 0.0551.125 ± 0.1170.0513707390.04420038

Differentially expression proteins on Day 3 comparing with control (ctrl) in hippocampus post ANOVA analysis.

These results indicate that protein expression is likely to be enhanced rather than prohibited in modulating seizures. Moreover, the expression levels of only 16 proteins were upregulated on both day 1 and day 3, while only five proteins were downregulated on both day 1 and day 3, suggesting that different molecules and pathways are involved in seizure events occurring from day 1 to day 3 following lithium-pilocarpine administration.

These results also suggest that the decreased number of upregulated proteins from day 1 to day 3 following lithium-pilocarpine administration may illustrate the possibility that the early phase of seizure events requires more molecules and activated pathways than are necessary in the late phase. Indeed, comparing day 3 to day 1 following lithium-pilocarpine administration, we found that 14 proteins were promoted and 37 proteins were impeded. Thus, only two upregulated proteins were the same on days 1 and 3 following lithium-pilocarpine administration (Table 3). These results suggest that epileptic events on day 1 and day 3 following lithium-pilocarpine administration require different molecules and different pathways for effective facilitation.

TABLE 3

Protein accessionProtein descriptionGene nameMean ± SEM
(Day 1)
Mean ± SEM
(Day 3)
Mean ± SEM
(ctrl)
P-value
(Day 1/Day 3/ctrl)
P-value
(Day 3/Day 1)
A0A0G2JVP4Immunoglobulin heavy constant muIghm0.859 ± 0.0711.182 ± 0.0750.969 ± 0.1020.0112121460.00963031
A0A0U1RRP1Synaptogyrin-1 (Fragment)Syngr10.895 ± 0.0621.085 ± 0.0761.031 ± 0.0630.0302838020.02934154
D3ZA45Autophagy-related protein 13Atg130.91 ± 0.041.121 ± 0.0710.975 ± 0.0570.0106031830.00946380
D3ZQN3PNMA family member 8BPnma8b0.887 ± 0.0591.086 ± 0.0841.034 ± 0.050.0218029570.02188623
D4A469Sestrin 3Sesn30.872 ± 0.1371.219 ± 0.1190.919 ± 0.0780.0243857030.02685536
D4A542G protein-coupled receptor-associated sorting protein 2Gprasp20.893 ± 0.0831.087 ± 0.0521.03 ± 0.0430.0243008160.02332960
D4AAI8Adhesion G protein-coupled receptor G7Adgrg70.916 ± 0.0461.108 ± 0.0530.982 ± 0.0590.0126696510.01100500
F1M8H7Actin-associated protein FAM107AFam107a0.768 ± 0.0571.146 ± 0.0231.079 ± 0.0260.00007720.0000932
G3V7Z4Glia-derived nexinSerpine20.812 ± 0.0441.124 ± 0.0771.09 ± 0.0640.0011050920.00149315
G3V917Protein TANC1Tanc10.922 ± 0.0441.167 ± 0.160.941 ± 0.0080.0334187060.04178967
H9N1L3BCL11B, BAF complex componentBcl11b0.9 ± 0.0661.101 ± 0.0581.005 ± 0.0930.0454686260.0383876
P97577Fasciculation and elongation protein zeta-1Fez10.877 ± 0.0451.057 ± 0.0731.015 ± 0.0620.0213400530.02207026
Q9R1K8RAS guanyl-releasing protein 1Rasgrp10.861 ± 0.0971.145 ± 0.0481.003 ± 0.1110.028494260.02374808
Q9Z122Acyl-CoA 6-desaturaseFads20.791 ± 0.0231.118 ± 0.1291.106 ± 0.0260.0014494120.00234218
A0A0A0MY39ATP-binding cassette sub-family B member 9Abcb91.246 ± 0.160.922 ± 0.0420.839 ± 0.0710.0047604010.01779094
A0A0G2JTL7RBR-type E3 ubiquitin transferaseAnkib11.126 ± 0.1040.893 ± 0.0980.984 ± 0.0670.0542415540.04650385
A0A0G2JY31Alpha-1-antiproteinaseSerpina11.395 ± 0.3240.868 ± 0.0850.735 ± 0.0480.0045972870.01874706
A0A0G2K1N9Selenoprotein OSelenoo1.048 ± 0.0650.868 ± 0.0771.093 ± 0.0770.0189825760.04683435
A0A0H2UHI5Serine protease inhibitorSerpina3n1.592 ± 0.2680.795 ± 0.2230.607 ± 0.0660.0023216110.01009321
A0A0H2UHP9RCG39700, isoform CRA_dRab6a1.158 ± 0.0650.964 ± 0.0670.881 ± 0.0520.0045237620.02576508
B1WBR8F-box and leucine-rich repeat protein 4Fbxl41.601 ± 0.1040.684 ± 0.040.703 ± 0.0490.00000580.0000093
D3Z899Mitoguardin 2Miga21.184 ± 0.1360.82 ± 0.1081.007 ± 0.0850.0177703090.01481953
D3ZGR7RCG51149Trir1.185 ± 0.0870.886 ± 0.0480.932 ± 0.0920.0085746150.00969835
D4A0W1ER membrane protein complex subunit 4Emc41.13 ± 0.050.903 ± 0.1150.911 ± 0.0680.029950420.04036656
D4A1U7Round spermatid basic protein 1Rsbn11.737 ± 0.1040.621 ± 0.0370.627 ± 0.0480.00000180.0000030
D4ABX8Leucine-rich repeat and fibronectin Type-III domain-containing protein 4Lrfn41.16 ± 0.0760.832 ± 0.0971.022 ± 0.150.0353249560.03040222
F1LST1FibronectinFn11.408 ± 0.0310.861 ± 0.0190.721 ± 0.0170.00000010.000001
F1LTD7DENN domain-containing 4CDennd4c1.096 ± 0.0470.896 ± 0.1051.014 ± 0.0570.0550195140.04824436
F1LTU4Ribosome assembly factor mrt4Mrto41.175 ± 0.080.911 ± 0.1260.911 ± 0.0480.0211223680.03101664
F1LZW6Solute carrier family 25 member 13Slc25a131.176 ± 0.1030.897 ± 0.0520.94 ± 0.0180.0039322350.00437097
G3V8F9Alpha-methylacyl-CoA racemaseAmacr1.096 ± 0.0530.867 ± 0.0541.048 ± 0.0910.0125440790.01337644
M0R965Uncharacterized proteinLOC6850251.265 ± 0.2030.902 ± 0.0810.837 ± 0.0460.0078749340.02131333
P02680Fibrinogen gamma chainFgg1.561 ± 0.3030.786 ± 0.030.648 ± 0.0670.0003358280.00139698
P02803Metallothionein-1Mt11.531 ± 0.1340.905 ± 0.2360.543 ± 0.0690.0014703080.02618866
P05943Protein S100-A10S100a101.637 ± 0.4730.698 ± 0.1440.645 ± 0.1860.0080898120.01664138
P06238Alpha-2-macroglobulinA2m1.361 ± 0.0470.962 ± 0.1470.666 ± 0.0740.0007929120.02149325
P06762Heme oxygenase 1Hmox11.687 ± 0.6220.826 ± 0.1070.491 ± 0.060.0019630840.02485557
P14480Fibrinogen beta chainFgb1.598 ± 0.3640.758 ± 0.0210.66 ± 0.0460.0005297150.00160255
P20059HemopexinHpx1.409 ± 0.1310.867 ± 0.120.708 ± 0.0410.0003975380.00231847
P55926Acid-sensing ion channel 1Asic11.088 ± 0.0620.904 ± 0.0721.007 ± 0.0820.0532008910.04568335
Q01984Histamine N-methyltransferaseHnmt1.009 ± 0.0910.822 ± 0.0891.181 ± 0.0010.004503680.04857169
Q3KR94VitronectinVtn1.281 ± 0.2010.832 ± 0.0450.885 ± 0.0740.0068816870.00815074
Q3T1J1Eukaryotic translation initiation factor 5A-1Eif5a1.288 ± 0.2030.781 ± 0.0690.952 ± 0.0530.0047865770.00397991
Q499P8RUS1 family protein C16orf58 homolog1.034 ± 0.0090.827 ± 0.010.951 ± 0.1110.0213714890.01825009
Q4FZZ3Glutathione S-transferase alpha-5Gsta51.898 ± 0.1240.571 ± 0.0470.51 ± 0.0340.00000090.0000021
Q4KLL7Vacuolar protein sorting 4 homolog BVps4b1.182 ± 0.050.888 ± 0.0370.939 ± 0.1530.0311165060.03461619
Q4KM86Gamma-glutamylaminecyclotransferaseGgact1.127 ± 0.1190.905 ± 0.0110.975 ± 0.0480.0221494490.01969118
Q5PPG5Chga proteinChga1.208 ± 0.0620.948 ± 0.0790.845 ± 0.0610.0021559170.01283758
Q68FY4Group specific componentGc1.316 ± 0.2560.857 ± 0.0140.833 ± 0.0270.0042325810.00825758
Q6AY91Nicotinamide riboside kinase 1Nmrk11.119 ± 0.1150.867 ± 0.0471.019 ± 0.0460.0132129650.01149958
Q7TQ70Ac1873Fga1.558 ± 0.3160.767 ± 0.0560.679 ± 0.0720.0006875670.00197323

Differentially expression proteins on Day 3 comparing with Day 1 in hippocampus post ANOVA analysis.

Subcellular distribution of differentially expressed proteins in the hippocampus

To predict the cellular functions of differentially expressed proteins, the locations of these proteins were analyzed in the current study. The total number of differentially expressed protein in the hippocampus was 117 on day 1 following lithium-pilocarpine administration (compared with controls). Using subcellular location analysis, the distribution was as follows: nucleus (26.5%, 31 proteins), extracellular (25.64%, 30 proteins), cytoplasm (24.79%, 29 proteins), mitochondria (7.69%, 9 proteins), plasma membrane (5.98%, 7 proteins), cytoplasm, nucleus (5.98%, 7 proteins), peroxisome (1.71%, two proteins, heme oxygenase 1, HMOX1; methylsterol monooxygenase 1, MSMO1), endoplasmic reticulum (0.85%, one protein, serine protease inhibitor, SERPINA3N), and cytoskeleton (0.85%, one protein, LisH domain-containing protein ARMC9, ARMC9) (Table 4). On day 3 following lithium-pilocarpine administration (as compared with controls), 59 proteins were distributed in the hippocampus as follows (as determined by subcellular location analysis): extracellular (29%, 17 proteins), the nucleus (22%, 13 proteins), cytoplasm (22%, 13 proteins), mitochondria (10%, six proteins), plasma membrane (8%, 5 proteins), cytoplasm and nucleus (7%, 4 proteins), and endoplasmic reticulum (2%, one protein, cell adhesion molecule L1-like, CHL1) (Table 5). The subcellular location of 51 differentially expressed proteins on day 3 following lithium-pilocarpine administration, compared with day 1, was as follows: the extracellular (25%, 13 proteins), nucleus (25%, 13 proteins), cytoplasm (20%, 10 proteins), plasma membrane (18%, 9 proteins), mitochondria (8%, 4 proteins), peroxisome (2%, 1 protein: HMOX1), and endoplasmic reticulum (2%, 1 protein, SERPINA3N) (Table 6).

TABLE 4

Subcellular localizationProtein accessionProtein descriptionGene nameMean ± SEM
(Day 1)
Mean ± SEM
(Day 3)
Mean ± SEM
(ctrl)
P-valuePost P-value
(Day 1/ctrl)
Regulated type
Nucleus (26.5%)F1LX28Acyl-CoA thioesterase 11Acot110.938 ± 0.0620.917 ± 0.1131.16 ± 0.0290.0244266380.047601114Down
F1M695YjeF N-terminal domain-containing 3Yjefn30.912 ± 0.0410.988 ± 0.0481.108 ± 0.040.0046149640.003820617Down
F1M8H7Actin-associated protein FAM107AFam107a0.768 ± 0.0571.146 ± 0.0231.079 ± 0.0260.00007720.000236951Down
G3V6S8Serine/arginine-rich splicing factor 6Srsf61.079 ± 0.0381.024 ± 0.0510.898 ± 0.0450.0063409980.005933366Up
Q9EPX0Heat shock protein beta-8Hspb81.167 ± 0.0611.009 ± 0.1090.826 ± 0.0120.003110310.002534785Up
M0R965Uncharacterized proteinLOC6850251.265 ± 0.2030.902 ± 0.0810.837 ± 0.0460.0078749340.008723589Up
O35821Myb-binding protein 1AMybbp1a1.135 ± 0.070.994 ± 0.0460.894 ± 0.0470.0051120570.004164782Up
P43278Histone H1.0H1f00.794 ± 0.0431.039 ± 0.2481.201 ± 0.120.0419641030.036372871Down
P6131460S ribosomal protein L15Rpl151.124 ± 0.0581.076 ± 0.1810.814 ± 0.0950.0399511660.044296005Up
P62804Histone H4Hist1h4b0.835 ± 0.0531.053 ± 0.1361.112 ± 0.1080.0313346730.032976035Down
Q3B8N7TSC22 domain family protein 4Tsc22d41.142 ± 0.1271.005 ± 0.1170.852 ± 0.0590.0360704820.030436262Up
Q5U3Y8Transcription factor BTF3Btf31.108 ± 0.0470.986 ± 0.0430.91 ± 0.010.0015144940.001244569Up
Q6QI89Mortality factor 4-like protein 2Morf4l21.175 ± 0.1351.017 ± 0.0160.813 ± 0.0580.0034107560.002867195Up
Q5XI28Ribonucleoprotein PTB-binding 1Raver11.114 ± 0.0881.022 ± 0.0920.87 ± 0.0950.041982810.037441659Up
F1LU97SAM and SH3 domain-containing 1Sash10.852 ± 0.0640.989 ± 0.0951.167 ± 0.1580.0318219820.026564789Down
D4A563Pseudopodium-enriched atypical kinase 1Peak11.065 ± 0.1231.035 ± 0.0270.875 ± 0.0410.0360898690.04251408Up
D3ZB76DnaJ (Hsp40) homolog, subfamily B, member 5 (Predicted)Dnajb51.135 ± 0.0880.994 ± 0.0270.875 ± 0.0120.0017044280.001359745Up
D3ZXL5Nuclear cap-binding subunit 3Ncbp31.124 ± 0.1711.033 ± 0.1070.848 ± 0.0360.0487546090.045718377Up
D4A1U7Round spermatid basic protein 1Rsbn11.737 ± 0.1040.621 ± 0.0370.627 ± 0.0480.00000180.0000031Up
A0A0G2K654Histone cluster 1 H1 family member cHist1h1c0.749 ± 0.0851.017 ± 0.0961.254 ± 0.210.007921440.006647937Down
A0A0G2KA11Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2Prex20.855 ± 0.0711.005 ± 0.0931.111 ± 0.0790.0225753110.019371419Down
B2GV14Taxilin alphaTxlna1.112 ± 0.0380.987 ± 0.050.903 ± 0.0670.010158740.008415176Up
B2RYW7RCG26543, isoform CRA_bSrp141.118 ± 0.1210.973 ± 0.0980.883 ± 0.0250.0460597450.039736226Up
B5DF45TNF receptor-associated factor 6Traf60.928 ± 0.0560.963 ± 0.0541.119 ± 0.0580.0138046420.01466275Down
A0A0G2JYD1Ubiquitin-associated protein 2Ubap21.082 ± 0.0511.068 ± 0.0610.854 ± 0.0450.0025243320.003693646Up
D3ZBN0Histone H1.5Hist1h1b0.86 ± 0.0760.985 ± 0.0561.17 ± 0.1680.0351675780.029578354Down
D3ZGR7RCG51149Trir1.185 ± 0.0870.886 ± 0.0480.932 ± 0.0920.0085746150.022044093Up
D3ZIF0Zinc finger protein 512Zfp5120.688 ± 0.0491.112 ± 0.3311.208 ± 0.2190.0460577720.048803418Down
D3ZML3Cyclin-dependent kinase 11BCdk11b1.119 ± 0.0560.979 ± 0.050.91 ± 0.0280.0039175020.003392973Up
D3ZMQ0MGA, MAX dimerization proteinMga1.125 ± 0.1080.964 ± 0.0290.919 ± 0.0460.0211655790.021150701Up
D3ZA21Pleckstrin homology and RhoGEF domain-containing G3Plekhg30.881 ± 0.1291.002 ± 0.0481.128 ± 0.0210.033156670.027745196Down
Extracellular (25.64%)P06238Alpha-2-macroglobulinA2m1.361 ± 0.0470.962 ± 0.1470.666 ± 0.0740.0007929120.000628868Up
P14480Fibrinogen beta chainFgb1.598 ± 0.3640.758 ± 0.0210.66 ± 0.0460.0005297150.000620191Up
P16975SPARCSparc1.08 ± 0.0571.053 ± 0.1180.874 ± 0.0330.0256904820.030097449Up
P20059HemopexinHpx1.409 ± 0.1310.867 ± 0.120.708 ± 0.0410.0003975380.000368949Up
Q3KR94VitronectinVtn1.281 ± 0.2010.832 ± 0.0450.885 ± 0.0740.0068816870.016683615Up
Q5PPG2LegumainLgmn1.091 ± 0.0741.091 ± 0.2010.794 ± 0.0540.0358606330.049602943Up
Q5XI90Dynein light chain Tctex-type 3Dynlt30.786 ± 0.1710.844 ± 0.1951.387 ± 0.1450.0240118070.029094976Down
Q63041Alpha-1-macroglobulinA1m1.162 ± 0.1861.009 ± 0.0670.86 ± 0.0730.0550490970.046839218Up
Q68FY4Group specific componentGc1.316 ± 0.2560.857 ± 0.0140.833 ± 0.0270.0042325810.005987128Up
Q6P734Plasma protease C1 inhibitorSerping11.229 ± 0.0271 ± 0.1690.771 ± 0.0260.0032619210.002631873Up
Q7TQ70Ac1873Fga1.558 ± 0.3160.767 ± 0.0560.679 ± 0.0720.0006875670.000821385Up
Q9QZK5Serine protease HTRA1Htra11.39 ± 0.4850.916 ± 0.0890.715 ± 0.0120.022516020.01927177Up
P02803Metallothionein-1Mt11.531 ± 0.1340.905 ± 0.2360.543 ± 0.0690.0014703080.001174416Up
Q5PPG5Chga proteinChga1.208 ± 0.0620.948 ± 0.0790.845 ± 0.0610.0021559170.001929208Up
P02680Fibrinogen gamma chainFgg1.561 ± 0.3030.786 ± 0.030.648 ± 0.0670.0003358280.00034631Up
P35355Prostaglandin G/H synthase 2Ptgs21.493 ± 0.5430.985 ± 0.2130.526 ± 0.0710.0067107570.00566147Up
G3V8D0ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3St8sia31.06 ± 0.0681.089 ± 0.0640.858 ± 0.0710.0100777930.021673603Up
A0A0G2JY31Alpha-1-antiproteinaseSerpina11.395 ± 0.3240.868 ± 0.0850.735 ± 0.0480.0045972870.004442122Up
A0A0G2K5J5Netrin G2Ntng21.165 ± 0.130.991 ± 0.0840.844 ± 0.0570.0133490570.010926122Up
A0A0G2K624Brain-derived neurotrophic factorBdnf1.143 ± 0.1511.08 ± 0.0680.778 ± 0.0890.0082416530.009860647Up
A0A0G2K946SPARC/osteonectin, cwcv and kazal-like domains proteoglycan 2Spock20.924 ± 0.0420.979 ± 0.0131.114 ± 0.0320.0010524580.000947972Down
F1LP80Neurosecretory protein VGFVgf1.266 ± 0.11.041 ± 0.140.691 ± 0.0420.0008455720.000742592Up
F1LR84Neuronal pentraxin-2Nptx21.134 ± 0.0931.183 ± 0.3740.687 ± 0.0310.0319458840.049143426Up
D3ZHV3MetallothioneinMt1m1.378 ± 0.2061.092 ± 0.4330.47 ± 0.0320.0090315720.008623115Up
F1LST1FibronectinFn11.408 ± 0.0310.861 ± 0.0190.721 ± 0.0170.00000010.0000001Up
F7EUK4Kininogen-1Kng11.535 ± 0.1021.012 ± 0.4240.44 ± 0.1120.0041426260.003524826Up
G3V714Neuroendocrine protein 7B2Scg50.937 ± 0.0520.982 ± 0.0421.139 ± 0.0740.0116701510.011575582Down
G3V7K3CeruloplasminCp1.232 ± 0.1890.981 ± 0.2350.799 ± 0.0230.0563006250.048127174Up
G3V7Z4Glia-derived nexinSerpine20.812 ± 0.0441.124 ± 0.0771.09 ± 0.0640.0011050920.002519461Down
P01048T-kininogen 1Map11.385 ± 0.3811.059 ± 0.5890.538 ± 0.0790.0431082940.037977515Up
Cytoplasm (24.79%)A0A0G2JX25GMP reductaseGmpr20.889 ± 0.1060.987 ± 0.0561.118 ± 0.0470.0355146470.02978354Down
Q9WVJ6Tissue-type transglutaminaseTgm21.204 ± 0.060.982 ± 0.1720.826 ± 0.0150.0139102870.011555675Up
Q9EST6Acidic leucine-rich nuclear phosphoprotein 32 family member BAnp32b1.124 ± 0.0540.959 ± 0.0520.924 ± 0.0420.0059666980.006510222Up
Q66HA8Heat shock protein 105 kDaHsph11.087 ± 0.0311.027 ± 0.0890.885 ± 0.0190.009002240.008450019Up
Q5HZA2Sprouty RTK-signaling antagonist 2Spry21.103 ± 0.1171.059 ± 0.0740.845 ± 0.0790.0255699120.029512024Up
Q4FZZ3Glutathione S-transferase Alpha-5Gsta51.898 ± 0.1240.571 ± 0.0470.51 ± 0.0340.00000090.0000014Up
Q3T1J1Eukaryotic translation initiation factor 5A-1Eif5a1.288 ± 0.2030.781 ± 0.0690.952 ± 0.0530.0047865770.041311914Up
Q02765Cathepsin SCtss1.262 ± 0.0970.884 ± 0.1310.855 ± 0.1620.0275586510.034687309Up
P6291260S ribosomal protein L32Rpl321.087 ± 0.0561.034 ± 0.1070.875 ± 0.0470.028430890.028255172Up
P59895Serine/threonine-protein kinase Nek6Nek61.179 ± 0.1660.939 ± 0.1020.887 ± 0.0560.0440209970.046634981Up
P30713Glutathione S-transferase theta-2Gstt21.146 ± 0.1150.982 ± 0.0260.875 ± 0.0670.0122062290.010099762Up
P05943Protein S100-A10S100a101.637 ± 0.4730.698 ± 0.1440.645 ± 0.1860.0080898120.010515729Up
O35760Isopentenyl-diphosphate Delta-isomerase 1Idi11.104 ± 0.0081.006 ± 0.0740.912 ± 0.0830.0376231310.031500687Up
O35547Long-chain-fatty-acid–CoA ligase 4Acsl41.108 ± 0.0780.987 ± 0.0470.919 ± 0.0280.0139007160.011886134Up
Q63357Unconventional myosin-IdMyo1d0.909 ± 0.0621 ± 0.0731.108 ± 0.0870.0425868770.035800118Down
F1LZW6Solute carrier family 25 member 13Slc25a131.176 ± 0.1030.897 ± 0.0520.94 ± 0.0180.0039322350.011410437Up
A0A0G2K7W6Similar to 60S ribosomal protein L27aRGD15624021.075 ± 0.0871.045 ± 0.1270.838 ± 0.0590.0353768460.041811288Up
A0A0G2QC03Influenza virus NS1A-binding proteinIvns1abp1.123 ± 0.071.016 ± 0.0760.861 ± 0.130.0433823640.038141301Up
A0A0H2UHH940S ribosomal protein S24Rps241.089 ± 0.0391.068 ± 0.0940.837 ± 0.1130.0273336210.035307812Up
A0A0H2UHP9RCG39700, isoform CRA_dRab6a1.158 ± 0.0650.964 ± 0.0670.881 ± 0.0520.0045237620.004012812Up
B2RYK22-(3-amino-3-carboxypropyl)histidine synthase subunit 1Dph11.127 ± 0.1230.978 ± 0.0570.895 ± 0.0480.033088070.028558263Up
B1WC40Nuclear cap-binding protein subunit 2Ncbp21.123 ± 0.0150.947 ± 0.0480.934 ± 0.0390.0019776010.002786505Up
D3ZCB9Family with sequence similarity 92, member BFam92b0.913 ± 0.0521.022 ± 0.0411.112 ± 0.0720.0134096590.011172678Down
D3ZWS6N(alpha)-acetyltransferase 30, NatC catalytic subunitNaa301.08 ± 0.0381.057 ± 0.0790.862 ± 0.0290.0032763910.004270506Up
D3ZYJ5GRAM domain-containing 1BGramd1b0.943 ± 0.0570.933 ± 0.0871.136 ± 0.040.0173158290.030984495Down
D3ZYS7G3BP stress granule assembly factor 1G3bp11.082 ± 0.0371.002 ± 0.0520.896 ± 0.0480.008056890.006715078Up
D4A0W1ER membrane protein complex subunit 4Emc41.13 ± 0.050.903 ± 0.1150.911 ± 0.0680.029950420.049835285Up
D3ZBL6Nucleoporin 160Nup1601.123 ± 0.1071.071 ± 0.1350.805 ± 0.1150.0342141320.039021308Up
G3V9W2Tyrosine-protein kinaseJak11.072 ± 0.0471.043 ± 0.0640.885 ± 0.0560.0130130080.015147659Up
Mitochondria (7.69%)F1LTU4Ribosome assembly factor mrt4Mrto41.175 ± 0.080.911 ± 0.1260.911 ± 0.0480.0211223680.033445134Up
Q4KM45UPF0687 protein C20orf27 homolog1.086 ± 0.0771.035 ± 0.0920.864 ± 0.0250.0150086250.015455778Up
Q4KLZ1Transmembrane protein 186Tmem1860.917 ± 0.0530.96 ± 0.0961.133 ± 0.0060.019494870.020474501Down
G3V7342,4-dienoyl CoA reductase 1, mitochondrial, isoform CRA_aDecr11.081 ± 0.0531.026 ± 0.0640.896 ± 0.0240.0080053580.007554546Up
F1LPX0Mitochondrial intermediate peptidaseMipep0.904 ± 0.010.992 ± 0.0261.118 ± 0.0380.0001605030.000128185Down
D3ZR12Syntrophin, gamma 2Sntg21.097 ± 0.0871.068 ± 0.0810.834 ± 0.0930.0180113490.022843965Up
B1WBR8F-box and leucine-rich repeat protein 4Fbxl41.601 ± 0.1040.684 ± 0.040.703 ± 0.0490.00000580.0000113Up
A0A0G2K5T6RNA polymerase I and III subunit CPolr1c1.159 ± 0.0551.003 ± 0.1350.837 ± 0.0290.0109437220.008969521Up
A0A0A0MXY7Uncharacterized protein1.16 ± 0.0311.038 ± 0.1990.799 ± 0.0420.0257767790.023109735Up
Plasma membrane (5.98%)A0A0A0MY39ATP-binding cassette sub-family B member 9Abcb91.246 ± 0.160.922 ± 0.0420.839 ± 0.0710.0047604010.004728188Up
A0A0H2UHF5ATP-sensitive inward rectifier potassium channel 10Kcnj100.766 ± 0.010.985 ± 0.2371.211 ± 0.130.0277078890.023028924Down
A0A1W2Q674ClaudinCldn100.889 ± 0.0571.014 ± 0.0171.104 ± 0.0840.0119838290.010179599Down
D4A017Transmembrane protein 87ATmem87a1.13 ± 0.1010.985 ± 0.1120.883 ± 0.0420.038235880.032409648Up
F1M0A0AnoctaminAno31.18 ± 0.1590.997 ± 0.1250.826 ± 0.1150.0487906390.041219969Up
P08050Gap junction alpha-1 proteinGja10.945 ± 0.060.898 ± 0.0331.183 ± 0.080.002514460.007650803Down
Q9Z122Acyl-CoA 6-desaturaseFads20.791 ± 0.0231.118 ± 0.1291.106 ± 0.0260.0014494120.002601096Down
Cytoplasm, nucleus (5.98%)P04961Proliferating cell nuclear antigenPcna1.232 ± 0.1810.965 ± 0.1610.779 ± 0.0340.0184474440.015287816Up
Q71UF4Histone-binding protein RBBP7Rbbp71.109 ± 0.1040.969 ± 0.0380.905 ± 0.0250.0164245340.014568544Up
P52631Signal transducer and activator of transcription 3Stat31.085 ± 0.071.065 ± 0.1720.815 ± 0.0090.0304203010.03815129Up
D3ZXL9Potassium channel tetramerization domain-containing 4Kctd40.931 ± 0.0870.903 ± 0.0321.172 ± 0.0260.0027453780.006217505Down
A0A0G2K2E2Antizyme inhibitor 2Azin21.092 ± 0.1541.111 ± 0.0180.804 ± 0.1250.0266245220.046602584Up
A0A096MJE3G1 to S phase transition 2Gspt21.13 ± 0.0730.946 ± 0.0150.93 ± 0.1040.0371137030.044872317Up
B2RYI0WD repeat-containing protein 91Wdr910.899 ± 0.0451.027 ± 0.0231.084 ± 0.0120.0010551910.000976489Down
Peroxisome (1.71%)P06762Heme oxygenase 1Hmox11.687 ± 0.6220.826 ± 0.1070.491 ± 0.060.0019630840.001591598Up
O35532Methylsterol monooxygenase 1Msmo11.117 ± 0.0460.982 ± 0.0830.906 ± 0.0360.0129413430.011098348Up
Cytoskeleton (0.85%)A0A0G2K9J8LisH domain-containing protein ARMC9Armc91.108 ± 0.1631.033 ± 0.0350.853 ± 0.0610.0417362270.04131062Up
Endoplasmic reticulum (0.85%)A0A0H2UHI5Serine protease inhibitorSerpina3n1.592 ± 0.2680.795 ± 0.2230.607 ± 0.0660.0023216110.002250448Up

Cellular distribution of differentially expression proteins on Day 1 comparing with control (ctrl) by ANOVA analysis in hippocampus.

TABLE 5

Subcellular localizationProtein accessionProtein descriptionGene nameMean ± SEM (Day 1)Mean ± SEM (Day 3)Mean ± SEM (ctrl)P-valuePost P-value (Day 3/ctrl)Regulated type
Extracellular (29%)O35263Platelet-activating factor acetylhydrolase IB subunit gammaPafah1b31.003 ± 0.0721.135 ± 0.1410.886 ± 0.0490.0389260.032614Up
Q6P734Plasma protease C1 inhibitorSerping11.229 ± 0.0271 ± 0.1690.771 ± 0.0260.0032620.044507Up
Q5XI90Dynein light chain Tctex-type 3Dynlt30.786 ± 0.1710.844 ± 0.1951.387 ± 0.1450.0240120.04766Down
Q3V5 × 8Endonuclease GEndog0.962 ± 0.0220.921 ± 0.0931.128 ± 0.0770.0281680.028427Down
P35355Prostaglandin G/H synthase 2Ptgs21.493 ± 0.5430.985 ± 0.2130.526 ± 0.0710.0067110.048988Up
P06238Alpha-2-macroglobulinA2m1.361 ± 0.0470.962 ± 0.1470.666 ± 0.0740.0007930.018911Up
O35314Secretogranin-1Chgb1.022 ± 0.021.093 ± 0.1160.88 ± 0.0430.0217030.020195Up
G3V8D0ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3St8sia31.06 ± 0.0681.089 ± 0.0640.858 ± 0.0710.0100780.012504Up
P02803Metallothionein-1Mt11.531 ± 0.1340.905 ± 0.2360.543 ± 0.0690.001470.041145Up
F1LR84Neuronal pentraxin-2Nptx21.134 ± 0.0931.183 ± 0.3740.687 ± 0.0310.0319460.045781Up
F1LP80Neurosecretory protein VGFVgf1.266 ± 0.11.041 ± 0.140.691 ± 0.0420.0008460.006023Up
F7EUK4Kininogen-1Kng11.535 ± 0.1021.012 ± 0.4240.44 ± 0.1120.0041430.030278Up
D3ZHV3MetallothioneinMt1m1.378 ± 0.2061.092 ± 0.4330.47 ± 0.0320.0090320.034986Up
D3ZDM7D-aspartate oxidaseDdo0.99 ± 0.0751.108 ± 0.0690.908 ± 0.080.0487420.041551Up
A0A0G2QC22PAXX, non-homologous end joining factorPaxx0.973 ± 0.0740.904 ± 0.0431.14 ± 0.0970.0201310.018321Down
A0A0G2K624Brain-derived neurotrophic factorBdnf1.143 ± 0.1511.08 ± 0.0680.778 ± 0.0890.0082420.019242Up
A0A0G2K3 × 6Uncharacterized protein1.014 ± 0.0710.857 ± 0.1181.141 ± 0.0970.036830.031574Down
Cytoplasm (22%)A0A0G2JWD6AP-3 complex subunit betaAp3b11.045 ± 0.0221.076 ± 0.0970.881 ± 0.0820.0375660.043753Up
P55063Heat shock 70 kDa protein 1-likeHspa1l0.807 ± 0.1041.472 ± 0.4860.731 ± 0.0820.024450.028127Up
P18484AP-2 complex subunit alpha-2Ap2a20.976 ± 0.0350.888 ± 0.0431.072 ± 0.0690.0111740.009119Down
G3V8F9Alpha-methylacyl-CoA racemaseAmacr1.096 ± 0.0530.867 ± 0.0541.048 ± 0.0910.0125440.034582Down
F1LV07Dynein, axonemal, heavy chain 9Dnah90.973 ± 0.0450.916 ± 0.0671.122 ± 0.0860.0252050.023287Down
F1LS29Calpain-1 catalytic subunitCapn10.999 ± 0.0831.103 ± 0.060.902 ± 0.0640.0351580.029378Up
Q01984Histamine N-methyltransferaseHnmt1.009 ± 0.0910.822 ± 0.0891.181 ± 0.0010.0045040.003676Down
D4A8F2Ras suppressor protein 1Rsu10.99 ± 0.0531.117 ± 0.1070.9 ± 0.0820.0519940.04422Up
D3ZYJ5GRAM domain-containing 1BGramd1b0.943 ± 0.0570.933 ± 0.0871.136 ± 0.040.0173160.023376Down
D3ZWS6N(alpha)-acetyltransferase 30, NatC catalytic subunitNaa301.08 ± 0.0381.057 ± 0.0790.862 ± 0.0290.0032760.007307Up
A0A0H2UHH940S ribosomal protein S24Rps241.089 ± 0.0391.068 ± 0.0940.837 ± 0.1130.0273340.048618Up
A0A0G2K890EzrinEzr0.988 ± 0.0661.147 ± 0.1970.853 ± 0.0290.0492780.041561Up
F1LQ22Unconventional SNARE in the ER 1Use11.046 ± 0.0541.082 ± 0.0720.871 ± 0.1090.0402270.045588Up
Nucleus (22%)P60825Cold-inducible RNA-binding proteinCirbp1.006 ± 0.0150.916 ± 0.0541.113 ± 0.0880.0179960.014819Down
Q6QI89Mortality factor 4-like protein 2Morf4l21.175 ± 0.1351.017 ± 0.0160.813 ± 0.0580.0034110.027886Up
Q9EPX0Heat shock protein beta-8Hspb81.167 ± 0.0611.009 ± 0.1090.826 ± 0.0120.003110.035314Up
Q5XI44X-ray repair complementing defective repair in Chinese hamster cells 4Xrcc41.026 ± 0.0271.085 ± 0.0470.893 ± 0.0490.0040510.003805Up
Q4W1H3Myosin 9bMyo9b0.982 ± 0.141.124 ± 0.0460.895 ± 0.0480.0525090.045919Up
P11530DystrophinDmd1.006 ± 0.0890.875 ± 0.0751.098 ± 0.0430.0257880.022128Down
A0A0G2JZ56Ankyrin 2Ank20.966 ± 0.0550.922 ± 0.0481.126 ± 0.0550.008530.008607Down
F1LX28Acyl-CoA thioesterase 11Acot110.938 ± 0.0620.917 ± 0.1131.16 ± 0.0290.0244270.029911Down
D3ZB30Polypyrimidine tract binding protein 1, isoform CRA_cPtbp11.029 ± 0.1171.087 ± 0.0490.893 ± 0.0190.0385450.035923Up
A0A0G2K2R0Uncharacterized protein0.991 ± 0.0470.897 ± 0.0531.123 ± 0.0460.004080.003317Down
A0A0G2K1W1RAB11 family-interacting protein 5Rab11fip51.054 ± 0.0511.072 ± 0.0660.885 ± 0.0910.0365430.04601Up
A0A0G2JYD1Ubiquitin-associated protein 2Ubap21.082 ± 0.0511.068 ± 0.0610.854 ± 0.0450.0025240.004909Up
G3V7R4Forkhead box protein O1Foxo10.969 ± 0.0860.906 ± 0.071.136 ± 0.1010.0445950.041773Down
Mitochondria (10%)Q499N5Acyl-CoA synthetase family member 2, mitochondrialAcsf21.011 ± 0.0340.888 ± 0.0891.1 ± 0.0430.0171280.014612Down
D4A7T8Family with sequence similarity 81, member AFam81a1.005 ± 0.040.885 ± 0.0761.104 ± 0.110.0411930.035271Down
D3ZZN3Acetyl-coenzyme A synthetaseAcss11.014 ± 0.1010.899 ± 0.0681.094 ± 0.0490.053260.046168Down
A0A0G2K6H2Maleylacetoacetate isomeraseGstz11.013 ± 0.1250.808 ± 0.1071.146 ± 0.120.0312480.027634Down
A0A0G2K1N9Selenoprotein OSelenoo1.048 ± 0.0650.868 ± 0.0771.093 ± 0.0770.0189830.02072Down
D3ZR12Syntrophin, gamma 2Sntg21.097 ± 0.0871.068 ± 0.0810.834 ± 0.0930.0180110.034845Up
Plasma membrane (8%)Q925D4Transmembrane protein 176BTmem176b1.05 ± 0.2051.242 ± 0.2170.714 ± 0.1880.0451130.041998Up
D3ZBN4Ergosterol biosynthesis 28 homologErg281.058 ± 0.1230.863 ± 0.0681.094 ± 0.0780.0379580.042839Down
P08050Gap junction alpha-1 proteinGja10.945 ± 0.060.898 ± 0.0331.183 ± 0.080.0025140.002788Down
P29534Vascular cell adhesion protein 1Vcam11.013 ± 0.0360.891 ± 0.0881.071 ± 0.0190.0225410.020949Down
Q9EP88Brain mitochondrial carrier protein BMCP1Slc25a140.986 ± 0.0850.898 ± 0.0551.125 ± 0.1170.0513710.0442Down
Cytoplasm, nucleus (7%)D3ZXL9Potassium channel tetramerization domain-containing 4Kctd40.931 ± 0.0870.903 ± 0.0321.172 ± 0.0260.0027450.003575Down
F1LVR8Myocardin-related transcription factor AMrtfa1.045 ± 0.1141.076 ± 0.0330.885 ± 0.0370.0325010.035827Up
A0A0G2K2E2Antizyme inhibitor 2Azin21.092 ± 0.1541.111 ± 0.0180.804 ± 0.1250.0266250.034925Up
B1WBV1Axin interactor, dorsalization-associatedAida0.995 ± 0.0671.117 ± 0.090.891 ± 0.0640.0271390.022541Up
Endoplasmic reticulum (2%)M0RC17Cell adhesion molecule L1-likeChl10.98 ± 0.0361.115 ± 0.1120.914 ± 0.0660.0459550.040653Up

Cellular distribution of differentially expression proteins on Day 3 comparing with control (ctrl) by ANOVA analysis in hippocampus.

TABLE 6

Subcellular localizationProtein accessionProtein descriptionGene nameMean ± SEM (Day 1)Mean ± SEM (Day 3)Mean ± SEM (ctrl)P-valuePost P-value (Day 3/Day 1)Regulated type
Extracellular (25%)Q3KR94VitronectinVtn1.281 ± 0.2010.832 ± 0.0450.885 ± 0.0740.0068816870.008150737Down
Q7TQ70Ac1873Fga1.558 ± 0.3160.767 ± 0.0560.679 ± 0.0720.0006875670.001973234Down
Q68FY4Group specific componentGc1.316 ± 0.2560.857 ± 0.0140.833 ± 0.0270.0042325810.008257581Down
Q5PPG5Chga proteinChga1.208 ± 0.0620.948 ± 0.0790.845 ± 0.0610.0021559170.012837584Down
Q4KM86Gamma-glutamylaminecyclotransferaseGgact1.127 ± 0.1190.905 ± 0.0110.975 ± 0.0480.0221494490.019691184Down
P20059HemopexinHpx1.409 ± 0.1310.867 ± 0.120.708 ± 0.0410.0003975380.002318468Down
F1LST1FibronectinFn11.408 ± 0.0310.861 ± 0.0190.721 ± 0.0170.00000010.0000007Down
P06238Alpha-2-macroglobulinA2m1.361 ± 0.0470.962 ± 0.1470.666 ± 0.0740.0007929120.021493248Down
P02803Metallothionein-1Mt11.531 ± 0.1340.905 ± 0.2360.543 ± 0.0690.0014703080.026188657Down
P02680Fibrinogen gamma chainFgg1.561 ± 0.3030.786 ± 0.030.648 ± 0.0670.0003358280.001396984Down
G3V7Z4Glia-derived nexinSerpine20.812 ± 0.0441.124 ± 0.0771.09 ± 0.0640.0011050920.001493145Up
A0A0G2JY31Alpha-1-antiproteinaseSerpina11.395 ± 0.3240.868 ± 0.0850.735 ± 0.0480.0045972870.018747055Down
P14480Fibrinogen beta chainFgb1.598 ± 0.3640.758 ± 0.0210.66 ± 0.0460.0005297150.001602549Down
Nucleus (25%)Q9R1K8RAS guanyl-releasing protein 1Rasgrp10.861 ± 0.0971.145 ± 0.0481.003 ± 0.1110.028494260.023748075Up
Q4KLL7Vacuolar protein sorting 4 homolog BVps4b1.182 ± 0.050.888 ± 0.0370.939 ± 0.1530.0311165060.034616193Down
M0R965Uncharacterized proteinLOC6850251.265 ± 0.2030.902 ± 0.0810.837 ± 0.0460.0078749340.021313333Down
H9N1L3BCL11B, BAF complex componentBcl11b0.9 ± 0.0661.101 ± 0.0581.005 ± 0.0930.0454686260.0383876Up
G3V917Protein TANC1Tanc10.922 ± 0.0441.167 ± 0.160.941 ± 0.0080.0334187060.041789671Up
F1M8H7Actin-associated protein FAM107AFam107a0.768 ± 0.0571.146 ± 0.0231.079 ± 0.0260.00007720.0000932Up
P97577Fasciculation and elongation protein zeta-1Fez10.877 ± 0.0451.057 ± 0.0731.015 ± 0.0620.0213400530.022070258Up
D4A1U7Round spermatid basic protein 1Rsbn11.737 ± 0.1040.621 ± 0.0370.627 ± 0.0480.00000180.0000030Down
D3ZQN3PNMA family member 8BPnma8b0.887 ± 0.0591.086 ± 0.0841.034 ± 0.050.0218029570.021886231Up
D3ZGR7RCG51149Trir1.185 ± 0.0870.886 ± 0.0480.932 ± 0.0920.0085746150.009698347Down
A0A0G2JVP4Immunoglobulin heavy constant muIghm0.859 ± 0.0711.182 ± 0.0750.969 ± 0.1020.0112121460.009630313Up
A0A0G2JTL7RBR-type E3 ubiquitin transferaseAnkib11.126 ± 0.1040.893 ± 0.0980.984 ± 0.0670.0542415540.046503851Down
D4A542G protein-coupled receptor-associated sorting protein 2Gprasp20.893 ± 0.0831.087 ± 0.0521.03 ± 0.0430.0243008160.023329603Up
Cytoplasm (20%)A0A0H2UHP9RCG39700, isoform CRA_dRab6a1.158 ± 0.0650.964 ± 0.0670.881 ± 0.0520.0045237620.025765079Down
Q6AY91Nicotinamide riboside kinase 1Nmrk11.119 ± 0.1150.867 ± 0.0471.019 ± 0.0460.0132129650.011499578Down
Q3T1J1Eukaryotic translation initiation factor 5A-1Eif5a1.288 ± 0.2030.781 ± 0.0690.952 ± 0.0530.0047865770.003979909Down
Q01984Histamine N-methyltransferaseHnmt1.009 ± 0.0910.822 ± 0.0891.181 ± 0.0010.004503680.048571688Down
P05943Protein S100-A10S100a101.637 ± 0.4730.698 ± 0.1440.645 ± 0.1860.0080898120.016641383Down
Q4FZZ3Glutathione S-transferase alpha-5Gsta51.898 ± 0.1240.571 ± 0.0470.51 ± 0.0340.0000010.0000021Down
F1LZW6Solute carrier family 25 member 13Slc25a131.176 ± 0.1030.897 ± 0.0520.94 ± 0.0180.0039322350.004370967Down
D4A0W1ER membrane protein complex subunit 4Emc41.13 ± 0.050.903 ± 0.1150.911 ± 0.0680.029950420.04036656Down
D3ZA45Autophagy-related protein 13Atg130.91 ± 0.041.121 ± 0.0710.975 ± 0.0570.0106031830.009463803Up
G3V8F9Alpha-methylacyl-CoA racemaseAmacr1.096 ± 0.0530.867 ± 0.0541.048 ± 0.0910.0125440790.013376436Down
Plasma membrane (18%)Q499P8RUS1 family protein C16orf58 homolog1.034 ± 0.0090.827 ± 0.010.951 ± 0.1110.0213714890.018250087Down
A0A0A0MY39ATP-binding cassette sub-family B member 9Abcb91.246 ± 0.160.922 ± 0.0420.839 ± 0.0710.0047604010.017790941Down
A0A0U1RRP1Synaptogyrin-1 (Fragment)Syngr10.895 ± 0.0621.085 ± 0.0761.031 ± 0.0630.0302838020.029341536Up
D3Z899Mitoguardin 2Miga21.184 ± 0.1360.82 ± 0.1081.007 ± 0.0850.0177703090.014819532Down
D4AAI8Adhesion G protein-coupled receptor G7Adgrg70.916 ± 0.0461.108 ± 0.0530.982 ± 0.0590.0126696510.011005002Up
D4ABX8Leucine-rich repeat and fibronectin type-III domain-containing protein 4Lrfn41.16 ± 0.0760.832 ± 0.0971.022 ± 0.150.0353249560.03040222Down
F1LTD7DENN domain-containing 4CDennd4c1.096 ± 0.0470.896 ± 0.1051.014 ± 0.0570.0550195140.048244363Down
P55926Acid-sensing ion channel 1Asic11.088 ± 0.0620.904 ± 0.0721.007 ± 0.0820.0532008910.04568335Down
Q9Z122Acyl-CoA 6-desaturaseFads20.791 ± 0.0231.118 ± 0.1291.106 ± 0.0260.0014494120.002342176Up
Mitochondria (8%)F1LTU4Ribosome assembly factor mrt4Mrto41.175 ± 0.080.911 ± 0.1260.911 ± 0.0480.0211223680.031016637Down
D4A469Sestrin 3Sesn30.872 ± 0.1371.219 ± 0.1190.919 ± 0.0780.0243857030.026855355Up
B1WBR8F-box and leucine-rich repeat protein 4Fbxl41.601 ± 0.1040.684 ± 0.040.703 ± 0.0490.00000580.0000093Down
A0A0G2K1N9Selenoprotein OSelenoo1.048 ± 0.0650.868 ± 0.0771.093 ± 0.0770.0189825760.046834353Down
Endoplasmic reticulum (2%)A0A0H2UHI5Serine protease inhibitorSerpina3n1.592 ± 0.2680.795 ± 0.2230.607 ± 0.0660.0023216110.010093209Down
Peroxisome (2%)P06762Heme oxygenase 1Hmox11.687 ± 0.6220.826 ± 0.1070.491 ± 0.060.0019630840.024855569Down

Cellular distribution of differentially expression proteins on Day 3 comparing with Day 1 by ANOVA analysis in hippocampus.

These results show that the number of subcellularly distributed proteins decreased by more than half on day 3 compared with that found on day 1 following lithium-pilocarpine administration, indicating that different cellular functions are required during seizure progression. Indeed, SERPINA3N was the only protein to be regulated in the endoplasmic reticulum, ARMC9 was the only proteins to be modulated in the cytoskeleton on day 1 following lithium-pilocarpine administration compared with controls (Table 4), and CHL1 was the only proteins to be modulated in the endoplasmic reticulum on day 3 following lithium-pilocarpine administration compared with controls (Table 5).

All of these results suggest that cellular function in the hippocampus following seizures is possibly regulated in a differential manner. On day 3 following lithium-pilocarpine administration (compared with day 1), shared 21 proteins among differentially regulated proteins distributed in subcellular locations, representing a small portion of regulated proteins (Tables 4, 5). On day 3 following lithium-pilocarpine administration (compared with day 1), 22 proteins were the same within day 1 following lithium-pilocarpine administration compared with controls (in evaluations conducted via subcellular analysis, Tables 4, 6), and only four proteins were same within day 3 following lithium-pilocarpine administration compared with controls (Tables 5, 6), suggesting that cells are recruited on a large scale in the mediation of early versus late seizure activity in the hippocampus. Moreover, alpha-2-macroglobulin (A2M), and Metallothionein-1 (MT1) were observed to be regulated on both day 1 and day 3 following lithium-pilocarpine administration (as compared with controls). Specifically, A2M, and MT1 were upregulated on both days, but the increases on day 3 were lower than that on day 1. To better understand the functionality of differentially expressed proteins, GO and KEGG pathway-based enrichment analyses were performed, as described below.

Gene ontology annotation and analysis of differentially expressed proteins

The number of differentially expressed proteins was calculated using level 2 GO terms according to GO annotation information, which contributed to characterization of their bio-functions. On day 1 following lithium-pilocarpine administration (compared with controls), 18 proteins were mapped within macromolecular complex assembly, 17 proteins were mapped within regulation of programmed cell death or regulation of apoptotic process, 20 proteins were mapped within negative regulation of programmed cell death, and five proteins were mapped within positive regulation of blood circulation in the “Biological Process” category (Figure 2A). A total of 18 proteins were clustered within RNA binding, six proteins were classified as peptidase inhibitor activity, endopeptidase regulator activity or endopeptidase inhibitor activity in the “Molecular Function” category (Figure 2B). A total of 101 proteins participated in extracellular exosome, vesicle, organelle, and region in the “Cellular Component” category (Figure 2C).

FIGURE 2

All these results indicate that, on day 1 following lithium-pilocarpine administration, macromolecular complex assembly, cell death and apoptotic process, blood circulation, RNA binding, and the extracellular regulation, were the main regulation targets in the hippocampus. On day 3 following lithium-pilocarpine administration (compared with controls), eight proteins were mapped within the negative regulation of protein metabolic process, four proteins were clustered within positive regulation of cell adhesion, or response to corticosteroid in the “Biological Process” category (Figure 2D). Thirty-three proteins were mapped to cytoplasm, 14 proteins were predicted within vesicle, and 4 proteins were mapped within cell-substrate junction in the “Cellular Component” category (Figure 2E). Moreover, seven proteins were mapped to identical protein binding, and three proteins were clustered within PDZ domain binding, endopeptidase inhibitor activity, endopeptidase regulator activity, or peptidase inhibitor activity in the “Molecular Function” category (Figure 2F).

In addition, all these results suggest that, on day 3 following lithium-pilocarpine administration, protein metabolic process rather than macromolecular complex assembly and cell death were affected in the hippocampus. In addition, on day 3 following the induced seizures (compared with day 1 following seizures), 10 proteins were clustered in macromolecular complex assembly, 8 proteins were mapped in the regulation of secretion by the cell, and 5 proteins were classified in the regulation of cell–cell adhesion in the “Biological Process” category (Figure 2G). Moreover, 17 proteins were mapped to the endomembrane system, 16 proteins were mapped to the extracellular region, 11 proteins were clustered within extracellular space, and 5 proteins were mapped to the secretory granule, or blood microparticle in the “Cellular Component” category (Figure 2H). Eight proteins were predicted in identical protein binding, seven proteins were mapped to protein homodimerization or dimerization activity, and three proteins were predicted in cell adhesion molecule binding or protein binding and bridging in the “Molecular Function” category (Figure 2I).

These results show that, on day 3 following lithium-pilocarpine administration (compared with day 1), the ECM, the constitution of plasma membranes, cell contact and secretion, and protein complexes in the hippocampus were altered in the development of seizure events.

Distribution and KEGG function analysis of differentially expressed proteins

KEGG pathway enrichment cluster analysis was performed to assess the possible involvement of signaling pathways in seizure events. On day 1 following lithium-pilocarpine administration, as compared with controls, 10 proteins were found to be clustered in the signaling pathway in cancer (regulating sustained angiogenesis and evading apoptosis); nine proteins were upregulated, indicating the cell death processes for further seizure events. This is in line with the findings of the GO analysis presented above.

Moreover, nine upregulated proteins were predicted in complement and coagulation cascades, which participate in inflammation response, cell lysis, and phagocytosis, and four proteins were mapped to pathways relevant to MicroRNAs in cancer. Three proteins (Fibronectin, FN; Kininogen 1, KNG1; T-kininogen 1, MAP1), all increased, represent pivotal pathways for modulating seizures; namely, regulatory processes for filopodia and lamellipodia of the actin cytoskeleton, the PI3K-Akt signaling pathway, platelet activation, cell adhesion molecules (CAMs) pathway, the nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway, the sphingolipid signaling pathway, the hypoxia-inducible factor 1 (HIF-1) signaling pathway, lysosomes, ECM-receptor interaction, and inflammatory mediator regulation of transient receptor potential (TRP) channels were all regulated (Figure 3A).

FIGURE 3

On day 3 following lithium-pilocarpine administration (compared with controls), the only indicated pathways were those relevant to Huntington’s disease, TNF signaling, NF-kappa B signaling, complement and coagulation cascades, MAPK signaling, PI3K-Akt signaling, apoptosis, regulation of the actin cytoskeleton, and protein processing in the endoplasmic reticulum. However, there were no more than four proteins in each pathway, indicating that the involved pathways were possibly less active on day 3 than on day 1 following lithium-pilocarpine administration (as compared with controls) (Figure 3B).

On day 3 following lithium-pilocarpine administration (as compared with on day 1), six proteins were found to participate in complement and coagulation cascades, four proteins were mapped in the pathway of cancer, or platelet activation. The minority of proteins were predicted to regulate were the PI3K-Akt signaling pathway, mineral absorption, proteoglycans (mediators of cancer tissue mechanics), and ECM-receptor interaction (in which only two proteins were involved) (Figure 3C).

Discussion

Epilepsy in an umbrella term that describes varieties of convulsive disorders. Studies on epileptogenesis have been conducted in animal models of SE, such as lithium-pilocarpine induced rodent animal models. The hippocampus is the primary site of epileptic activity. Therefore, we conducted a study to detect global protein expression in the hippocampus in SE induced by lithium-pilocarpine in order to understand seizure events in regard to late phase epileptogenesis. In our study, we identified 6,157 proteins in total and quantified 5,593 proteins. Most of the differentially expressed proteins were predicted to be upregulated in the hippocampus on days 1 and 3 following lithium-pilocarpine administration, indicating that protein expression was likely to be enhanced rather than prohibited in the modulation of seizures within SE. Moreover, the number of enhanced proteins in the hippocampus decreased by more than half from day 1 to day 3, and only a small portion of proteins were the same when comparing these timepoints, suggesting that different molecules and pathways are involved in epilepsy events occurring from day 1 to day 3 following lithium-pilocarpine administration.

In our study, several differential expression proteins involved in the phasing of seizure events, such as EIF5A. Previous work has demonstrated that reduced hypusinated EIF5A causes neurological impairment, including seizures (Ganapathi et al., 2019). Further, a prior study demonstrated that EIF5A regulated neuronal survival and growth (Huang et al., 2007), indicating that EIF5A and other molecules are upregulated in protecting neurons against the damage caused by seizures. Several roles of EIF5A have been reported; for example, neuronal apoptosis is regulated by EIF5A/p53 (Li et al., 2004), axonal growth of dorsal root ganglion (DRG) neurons is stimulated by brain-derived neurotrophic factor (BDNF)/arginase I/EIF5A/cAMP (Cai et al., 2002; Huang et al., 2007), and EIF5A variants have been found to cause several disorders, such as developmental delay, intellectual disability, facial dysmorphisms, and microcephaly (Park et al., 2022). Of note, EIF5A stabilizes ribosome components and promotes mRNA translation termination and elongation (Chen et al., 1996; Schuller et al., 2017). In our study, the levels of several ribosome components increased on day 1 following lithium-pilocarpine administration, suggesting the potential function of EIF5A in stabilizing ribosomes for mRNA transcription. However, on day 3 following lithium-pilocarpine administration, the levels of EIF5A and ribosome components were decreased and were similar to those of controls, suggesting neuron loss, apoptosis, and degeneration in the hippocampus.

In intractable epilepsy (IE), the neural network is reorganized to properly transduce signals; this is a prominent pathological change that leads to the transient expression of several molecules, such as netrin G2, fibronectin (Fn), and vitronectin. Netrin G2 has been shown to modulate synapse formation and neurite outgrowth (Lin et al., 2003; Kim et al., 2006). Moreover, the overexpression of netrin G2 within excitatory neurons in patients with IE and in the hippocampus of lithium-pilocarpine induced rat models is assumed to be commensurate with abnormal synapse development and neuron migration (Woo et al., 2009; Pan et al., 2010); this is in line with our findings reported here, as epileptic discharges and spreading are supported by abnormal synapses (Buckmaster et al., 2002). Moreover, synaptic reorganization promotes the development of the excitatory loop, and Fn and its integrin receptor are known to participate in the pathophysiology of epilepsy (Gall and Lynch, 2004; Dityatev and Fellin, 2008; Wu and Reddy, 2012; Pitkanen et al., 2014). Other studies in addition to our own have shown that Fn expression is increased in the hippocampus after a first behavioral seizure (Hoffman et al., 1998; Wu et al., 2017). Moreover, epileptogenesis is modulated by Fn by modulating neuronal cell plasticity and mechanical properties in the hippocampus in epilepsy via its integrin receptor (Wu et al., 2017). Fn is rapidly synthesized, which was assumed by proliferated astrocytes in the hippocampus of epileptic rats (Niquet et al., 1994; Hoffman et al., 1998), and Fn and integrin interactions modulate cell adhesion and membrane elasticity in epilepsy model mice (Wu et al., 2016). Some proliferated astrocytes produce vitronectin in the hippocampus, which is related with neuronal degeneration in rat models of kainic acid (KA)-induced seizures (Niquet et al., 1996). Taken together, these findings suggest that several molecules, especially ECM molecules, contribute to reorganizing the neural network for modulating excitotoxicity in seizures in the hippocampus in lithium-pilocarpine induced SE animal models.

Lack of mitochondrial intermediate peptidase (MIP) causes seizures (Eldomery et al., 2016). Tumor necrosis factor-α receptor-associated factor 6 (TRAF6) is a key element of the transforming growth factor beta (TGFβ)-associated inflammation pathway and activates TGFβ-activated kinase 1 (TAK1) (Takaesu et al., 2000); this further leads to promoting the expression of proinflammatory cytokines and to the aggravation of inflammation (Onodera et al., 2015). Moreover, molecule causing demyelination/hypomyelination, such as gap junction alpha-1 protein (GJA1), decreases in the hippocampus on day 1 in the epileptic rat; this shows that demyelination is present in the early phases of seizure development, which is in line with the findings of our previously published study (Hobson and Garbern, 2012; Yalcinkaya et al., 2012; Basu and Sarma, 2018; Li T. et al., 2020; Wang et al., 2021). The deficit of adenosine triphosphate (ATP)-sensitive inward rectifier potassium channel 10 (KCNJ10) causes seizures and myelin vacuolization (Phani et al., 2014; Larson et al., 2018; Zhu et al., 2020). Metallothionein-1 (MT1), a zinc binding protein, exerts neuroprotection by reducing proinflammatory responses, increasing neurotrophins, and delaying neuron degeneration (Penkowa et al., 2005). In MT1-deficient mice, seizures are enhanced and neurons in hippocampus are injured, leading to apoptosis (Carrasco et al., 2000). Moreover, higher hemopexin levels are detected in the serum of schizophrenic patients than in normal subjects (Clarke et al., 1970).

Signal transducer and activator of transcription 3 (STAT3) is highly expressed in children with epilepsy (Li Y. Z. et al., 2020). Moreover, SE induced by pilocarpine activates the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway and the STAT3-mediated signaling pathway and promotes neuronal cell death and glia activation by producing interleukin 1 beta (IL-1β) in mice with induced SE (Tian et al., 2017; Han et al., 2020). Further, inhibition of STAT3 decreases spontaneous seizure frequency and the severity of chronic epilepsy (Grabenstatter et al., 2014). DnaJ heat shock protein family member B5 (DNAJB5) and heat shock proteins (HSPs) (HSPH1 and HSPB8) are upregulated in the hippocampus of epileptic mice to protect neurons (Lee et al., 2021).

HMOX1 is upregulated in epileptic rats (Wang et al., 2013; Prakash et al., 2019), and previous studies have found that tissue-type transglutaminase (TGM2) is mostly produced by neurons in the mammalian nervous system and is elevated in neurodegenerative diseases as well as in response to acute CNS injury, which possibly induces neuronal cell death (Tucholski et al., 2006). Cathepsin S (CTSS) is mainly produced by microglia in the hippocampi of kainate-injected mice (Akahoshi et al., 2007), and prohibition of its function resulted in reducing inflammation and alleviating brain edema in a mouse model of traumatic brain injury (Xu et al., 2013). Proliferation cell nuclear antigen (PCNA) is highly expressed in epileptic animal models and in the human brain (Zhang et al., 2005; Liu et al., 2008). BDNF and the tropomyosin kinase receptor B (TRKB) pathway are predicted to function in the prevention or suppression of epilepsy targets (Lin et al., 2020; Sullivan and Kadam, 2021). The neurosecretory vascular growth factor (VGF) protein plays a critical role in the control of energy homeostasis, and the high expression of VGF in the CNS in seizure animal models is in line with a high requirement for energy (Salton et al., 2000). In addition, dystrophin is a component of gamma-aminobutyric acid (GABA)ergic synapses and plays a role in normal cognitive (i.e., episodic memory) processes (Knuesel et al., 2001; Hoogland et al., 2019); the absence of dystrophin is associated with epilepsy (Hoogland et al., 2019). Taken together, these findings provide a comprehensive picture of relevant pathways occurring during seizure development.

In conclusion, to the best of our knowledge, this study is to investigate global protein expression in the acute phase of epileptic seizures from lithium-pilocarpine induced rats using a tandem mass tag (TMT)-based proteomic approach and identified 6,157 differentially expressed proteins in total and 5,593 proteins quantified in the experimental and control groups. Of note, the majority of the differentially expressed proteins were predicted to be upregulated in the hippocampus on days 1 and 3 following lithium-pilocarpine administration, indicating that protein expression was likely to be enhanced rather than prohibited in the modulation of seizures within SE. Moreover, the number of enhanced proteins in the hippocampus decreased by more than half from day 1 to day 3, and only a small portion of proteins were the same when comparing day 1 to day 3, suggesting that different molecules and pathways are involved in epilepsy events occurring from day 1 to day 3 following lithium-pilocarpine administration. On day 1 following lithium-pilocarpine administration, as compared with controls, 10 proteins were found to be clustered in the signaling pathway in cancer (regulating sustained angiogenesis and evading apoptosis); nine proteins were upregulated, indicating the cell death processes for further seizure events. Moreover, nine upregulated proteins were predicted in complement and coagulation cascades, which participate in inflammation response, cell lysis, and phagocytosis, and four proteins were mapped to pathways relevant to MicroRNAs in cancer. On day 3 following lithium-pilocarpine administration (compared with controls), the only indicated pathways were those relevant to Huntington’s disease, TNF signaling, NF-kappa B signaling, etc., however, there were no more than four proteins in each pathway. On day 3 following lithium-pilocarpine administration (as compared with day 1), the majority of proteins were found to participate in complement and coagulation cascades, pathways relevant to cancer, and platelet activation. Our results suggest that the different molecules and pathways are involved in seizure events occurring from day 1 to day 3 following lithium-pilocarpine administration. These proteins may serve as candidate proteins for the development of seizure events and need to be studied further. Meanwhile, it is necessary to point out that the present study is a preliminary investigation. These differentially expressed proteins need to be further validated using other analyses, and a large-scale validation and a long-term strategy for proteomics analysis in the chronic phase of epileptic animals are also required.

Statements

Data availability statement

The datasets presented in this study can be found in online repositories. The data presented in the study are deposited in FTP repository, the website is ftp://115.238.71.26, the account number is: ptm_ftp_0935 and the accession number is: B4y171.

Ethics statement

This animal study was reviewed and approved by the National Institutes of Health and the Animal Welfare Committee of Ningxia Medical University (Ethics Approval Number: 2019-151, Ningxia, China).

Author contributions

PW and LY conceived and designed the experiments. LY, ZC, XR, and FW performed the experiments. RY, YJ, YD, and FY analyzed the data and collected the references. PW wrote the first draft. HM, TS, and PW checked and revised the draft. All authors approved the submission of this manuscript to be published.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81960232 and 82001282), the Key R&D Plan Project of Ningxia (2019BEB04041), Overseas Students’ Innovation and Entrepreneurship Individual Project of Ningxia (2021), Youth Talents Supporting Program of Ningxia Medical University and Ningxia (XT2019018 and TJGC2019081), and College Students’ Innovation and Entrepreneurship Training Program (X202210752038). These funders had no role in the design, conducts, or reporting of this work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AkahoshiN.MurashimaY. L.HimiT.IshizakiY.IshiiI. (2007). Increased expression of the lysosomal protease cathepsin S in hippocampal microglia following kainate-induced seizures.Neurosci. Lett.429136141. 10.1016/j.neulet.2007.10.007

  • 2

    AndréV.DubéC.FrancóisJ.LeroyC.RigoulotM. A.RochC.et al (2007). Pathogenesis and pharmacology of epilepsy in the lithium–pilocarpine model.Epilepsia484147. 10.1111/j.1528-1167.2007.01288.x

  • 3

    BasuR.SarmaJ. D. (2018). Connexin 43/47 channels are important for astrocyte/oligodendrocyte cross-talk in myelination and demyelination.J. Biosci.4310551068. 10.1007/s12038-018-9811-0

  • 4

    BegcevicI.KosanamH.Martínez-MorilloE.DimitromanolakisA.DiamandisP.KuzmanovU.et al (2013). Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains.Clin. Proteomics10:5. 10.1186/1559-0275-10-5

  • 5

    BuckmasterP. S.ZhangG. F.YamawakiR. (2002). Axon sprouting in a model of temporal lobe epilepsy creates a predominantly excitatory feedback circuit.J. Neurosci.2266506658. 10.1523/JNEUROSCI.22-15-06650.2002

  • 6

    CaiD.DengK.MelladoW.LeeJ.RatanR. R.FilbinM. T. (2002). Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro.Neuron35711719. 10.1016/s0896-6273(02)00826-7

  • 7

    CarrascoJ.PenkowaM.HadbergH.MolineroA.HidalgoJ. (2000). Enhanced seizures and hippocampal neurodegeneration following kainic acid-induced seizures in metallothionein-I + II-deficient mice.Eur. J. Neurosci.1223112322. 10.1046/j.1460-9568.2000.00128.x

  • 8

    CavalheiroE. A.LeiteJ. P.BortolottoZ. A.TurskiW. A.IkonomidouC.TurskiL. (1991). Long-term effects of pilocarpine in rats: Structural damage of the brain triggers kindling and spontaneous recurrent seizures.Epilepsia32778782.

  • 9

    ChakirA.FabeneP. F.OuazzaniR.BentivoglioM. (2006). Drug resistance and hippocampal damage after delayed treatment of pilocarpine-induced epilepsy in the rat.Brain Res. Bull.71127138.

  • 10

    ChenZ. P.YanY. P.DingQ. J.KnappS.PotenzaJ. A.SchugarH. J.et al (1996). Effects of inhibitors of deoxyhypusine synthase on the differentiation of mouse neuroblastoma and erythroleukemia cells.Cancer Lett.105233239. 10.1016/0304-3835(96)04287-5

  • 11

    ClarkeH. G.FreemanT.Pryse-PhillipsW. (1970). Quantitative immunoelectrophoresis of serum from hospitalized chronic schizophrenic and epileptic patients.J. Neurol. Neurosurg. Psychiatry33694697. 10.1136/jnnp.33.5.694

  • 12

    CliffordD. B.OlneyJ. W.ManiotisA.CollinsR. C.ZorumskiC. F. (1987). The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures.Neuroscience23953968.

  • 13

    DityatevA.FellinT. (2008). Extracellular matrix in plasticity and epileptogenesis.Neuron Glia Biol.4235247.

  • 14

    EdgarP. F.SchonbergerS. J.DeanB.FaullR. L.KyddR.CooperG. J. (1999b). A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer’s disease individuals.Mol. Psychiatry4173178. 10.1038/sj.mp.4000463

  • 15

    EldomeryM. K.AkdemirZ. C.VögtleF. N.CharngW. L.MulicaP.RosenfeldJ. A.et al (2016). MIPEP recessive variants cause a syndrome of left ventricular non-compaction, hypotonia, and infantile death.Genome Med.8:106. 10.1186/s13073-016-0360-6

  • 16

    FisherR. S.van Emde BoasW.BlumeW.ElgerC.GentonP.LeeP.et al (2005). Epileptic seizures and epilepsy: Definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE).Epilepsia46470472.

  • 17

    GallC. M.LynchG. (2004). Integrins, synaptic plasticity and epileptogenesis.Adv. Exp. Med. Biol.5481233.

  • 18

    GanapathiM.PadgettL. R.YamadaK.DevinskyO.WillaertR.PersonR.et al (2019). Recessive rare variants in deoxyhypusine synthase, an enzyme involved in the synthesis of hypusine, are associated with a neurodevelopmental disorder.Am. J. Hum. Genet.104287298. 10.1016/j.ajhg.2018.12.017

  • 19

    GlienM.BrandtC.PotschkaH.LöscherW. (2002). Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy.Epilepsia43350357.

  • 20

    GrabenstatterH. L.Del AngelY. C.CarlsenJ.WempeM. F.WhiteA. M.CogswellM.et al (2014). The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy.Neurobiol. Dis.627385. 10.1016/j.nbd.2013.09.003

  • 21

    HamiltonS. E.LooseM. D.QiM.LeveyA. I.HilleB.McKnightG. S.et al (1997). Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice.Proc. Natl. Acad. Sci. U.S.A.941331113316.

  • 22

    HanC. L.LiuY. P.GuoC. J.DuT. T.JiangY.WangK. L.et al (2020). The lncRNA H19 binding to let-7b promotes hippocampal glial cell activation and epileptic seizures by targeting Stat3 in a rat model of temporal lobe epilepsy.Cell Prolif.53:e12856. 10.1111/cpr.12856

  • 23

    HobsonG. M.GarbernJ. Y. (2012). Pelizaeus-Merzbacher disease. Pelizaeus-merzbacher-like disease 1, and related hypomyelinating disorders.Semin. Neurol.326267. 10.1055/s-0032-1306388

  • 24

    HoffmanK. B.PinkstaffJ. K.GallC. M.LynchG. (1998). Seizure induced synthesis of fibronectin is rapid and age dependent: Implications for long-term potentiation and sprouting.Brain Res.812209215.

  • 25

    HoncharM. P.OlneyJ. W.ShermanW. R. (1983). Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science220, 323325. 10.1126/science.6301005.

  • 26

    HondiusD. C.van NieropP.LiK. W.HoozemansJ. J. M.van der SchorsR. C.van HaastertE. S.et al (2016). Profiling the human hippocampal proteome at all pathologic stages of Alzheimer’s disease.Alzheimers Dement.12654668. 10.1016/j.jalz.2015.11.002

  • 27

    HooglandG.HendriksenR. G. F.SlegersR. J.HendriksM. P. H.SchijnsO. E. M. G.AalbersM. W.et al (2019). The expression of the distal dystrophin isoforms Dp140 and Dp71 in the human epileptic hippocampus in relation to cognitive functioning.Hippocampus29102110. 10.1002/hipo.23015

  • 28

    HuangY.HigginsonD. S.HesterL.ParkM. H.SnyderS. H. (2007). Neuronal growth and survival mediated by eIF5A, a polyamine-modified translation initiation factor.Proc. Natl. Acad. Sci. U.S.A.10441944199. 10.1073/pnas.0611609104

  • 29

    KimS.BuretteA.ChungH. S.KwonS. K.WooJ.LeeH. W.et al (2006). NGL family PSD-95-interacting adhesion molecules regulate excitatory synapse formation.Nat. Neurosci.912941301.

  • 30

    KnueselI.ZuelligR. A.SchaubM. C.FritschyJ. M. (2001). Alterations in dystrophin and utrophin expression parallel the reorganization of GABAergic synapses in a mouse model of temporal lobe epilepsy.Eur. J. Neurosci.1311131124. 10.1046/j.0953-816x.2001.01476.x

  • 31

    LarsonV. A.MironovaY.VanderpoolK. G.WaismanA.RashJ. E.AgarwalA.et al (2018). Oligodendrocytes control potassium accumulation in white matter and seizure susceptibility.eLife.7:e34829. 10.7554/eLife.34829

  • 32

    LeeT. S.LiA. Y.RapuanoA.MantisJ.EidT.SeyfriedT. N.et al (2021). Gene expression in the epileptic (EL) mouse hippocampus.Neurobiol. Dis.147:105152. 10.1016/j.nbd.2020.105152

  • 33

    LeiteJ. P.BortolottoZ. A.CavalheiroE. A. (1990). Spontaneous recurrent seizures in rats: An experimental model of partial epilepsy.Neurosci. Biobehav. Rev.14511517.

  • 34

    LiA. L.LiH. Y.JinB. F.YeQ. N.ZhouT.YuX. D.et al (2004). A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis.J. Biol. Chem.2794925149258. 10.1074/jbc.M407165200

  • 35

    LiT.NiuJ.YuG.EzanP.YiC.WangX.et al (2020). Connexin 43 deletion in astrocytes promotes CNS remyelination by modulating local inflammation.Glia6812011212. 10.1002/glia.23770

  • 36

    LiY. Z.ZhangL.LiuQ.BianH. T.ChengW. J. (2020). The effect of single nucleotide polymorphisms of STAT3 on epilepsy in children.Eur. Rev. Med. Pharmacol. Sci.24837842. 10.26355/eurrev_202001_20067

  • 37

    LinJ. C.HoW. H.GurneyA.RosenthalA. (2003). The netrin-G1 ligand NGL-1 promotes the outgrowth of thalamocortical axons.Nat. Neurosci.612701276.

  • 38

    LinT. W.HarwardS. C.HuangY. Z.McNamaraJ. O. (2020). Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy.Neuropharmacology167:107734. 10.1016/j.neuropharm.2019.107734

  • 39

    LiuY. W.CurtisM. A.GibbonsH. M.MeeE. W.BerginP. S.TeohH. H.et al (2008). Doublecortin expression in the normal and epileptic adult human brain.Eur. J. Neurosci.2822542265. 10.1111/j.1460-9568.2008.06518.x

  • 40

    NiquetJ.GillianA.Ben-AriY.RepresaA. (1996). Reactive glial cells express a vitronectin-like protein in the hippocampus of epileptic rats.Glia16359367. 10.1002/(SICI)1098-1136(199604)16:4<359:AID-GLIA8<3.0.CO;2-V

  • 41

    NiquetJ.JorqueraI.Ben-AriY.RepresaA. (1994). Proliferative astrocytes may express fibronectin-like protein in the hippocampus of epileptic rats.Neurosci. Lett.1801316. 10.1016/0304-3940(94)90902-4

  • 42

    OnoderaY.TeramuraT.TakeharaT.ShigiK.FukudaK. (2015). Reactive oxygen species induce Cox-2 expression via TAK1 activation in synovial fibroblast cells.FEBS Open Bio.5492501. 10.1016/j.fob.2015.06.001

  • 43

    PanY.LiuG.FangM.ShenL.WangL.HanY.et al (2010). Abnormal expression of netrin-G2 in temporal lobe epilepsy neurons in humans and a rat model.Exp. Neurol.224340346. 10.1016/j.expneurol.2010.04.001

  • 44

    ParkM. H.KarR. K.BankaS.ZieglerA.ChungW. K. (2022). Post-translational formation of hypusine in eIF5A: Implications in human neurodevelopment.Amino Acids54485499. 10.1007/s00726-021-03023-6

  • 45

    PenkowaM.FloritS.GiraltM.QuintanaA.MolineroA.CarrascoJ.et al (2005). Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures.J. Neurosci. Res.79522534. 10.1002/jnr.20387

  • 46

    PersikeD. S.Marques-CarneiroJ. E.SteinM. L. D. L.YacubianE. M. T.CentenoR.CanzianM.et al (2018). Altered proteins in the hippocampus of patients with mesial temporal lobe epilepsy.Pharmaceuticals (Basel).11:E95. 10.3390/ph11040095

  • 47

    PersikeD.LimaM.AmorimR.CavalheiroE.YacubianE.CentenoR.et al (2012). Hippocampal proteomic profile in temporal lobe epilepsy.J. Epilepsy Clin. Neurophysiol.185356. 10.1590/S1676-26492012000200007

  • 48

    PhaniN. M.AcharyaS.XavyS.BhaskaranandN.BhatM. K.JainA.et al (2014). Genetic association of KCNJ10 rs1130183 with seizure susceptibility and computational analysis of deleterious non-synonymous SNPs of KCNJ10 gene.Gene536247253. 10.1016/j.gene.2013.12.026

  • 49

    PitkanenA.Ndode-EkaneX. E.LukasiukK.WilczynskiG. M.DityatevA.WalkerM. C.et al (2014). Neural ECM and epilepsy.Prog. Brain Res.214229262.

  • 50

    PrakashC.MishraM.KumarP.KumarV.SharmaD. (2019). Dehydroepiandrosterone alleviates oxidative stress and apoptosis in iron-induced epilepsy via activation of Nrf2/ARE signal pathway.Brain Res. Bull.153181190. 10.1016/j.brainresbull.2019.08.019

  • 51

    PrielM. R.AlbuquerqueE. X. (2002). Short-term effects of pilocarpine on rat hippocampal neurons in culture.Epilepsia434046.

  • 52

    RacineR. J. (1972). Modification of seizure activity by electrical stimulation. II. Motor seizure.Electroencephalogr. Clin. Neurophysiol.32281294. 10.1016/0013-4694(72)90177-0

  • 53

    SadeghiL.RizvanovA. A.DabirmaneshB.SalafutdinovI. I.SayyahM.ShojaeiA.et al (2021). Proteomic profiling of the rat hippocampus from the kindling and pilocarpine models of epilepsy: Potential targets in calcium regulatory network.Sci. Rep.11:8252. 10.1038/s41598-021-87555-7

  • 54

    SaltonS. R.FerriG. L.HahmS.SnyderS. E.WilsonA. J.PossentiR.et al (2000). VGF: A novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance.Front. Neuroendocrinol.21:199219. 10.1006/frne.2000.0199

  • 55

    SchullerA. P.WuC. C.DeverT. E.BuskirkA. R.GreenR. (2017). eIF5A functions globally in translation elongation and termination.Mol. Cell66194.e205.e.

  • 56

    SullivanB. J.KadamS. D. (2021). Brain-derived neurotrophic factor in neonatal seizures.Pediatr. Neurol.1183539. 10.1016/j.pediatrneurol.2021.01.011

  • 57

    SultanaR.Boyd-KimballD.CaiJ.PierceW. M.KleinJ. B.MerchantM.et al (2007). Proteomics analysis of the Alzheimer’s disease hippocampal proteome.J. Alzheimers Dis.11153164. 10.3233/jad-2007-11203

  • 58

    TakaesuG.KishidaS.HiyamaA.YamaguchiK.ShibuyaH.IrieK.et al (2000). TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway.Mol. Cell5649658. 10.1016/s1097-2765(00)80244-0

  • 59

    TianD. S.PengJ.MuruganM.FengL. J.LiuJ. L.EyoU. B.et al (2017). Chemokine CCL2-CCR2 signaling induces neuronal cell death via STAT3 activation and IL-1β production after status epilepticus.J. Neurosci.3778787892. 10.1523/JNEUROSCI.0315-17.2017

  • 60

    TucholskiJ.RothK. A.JohnsonG. V. (2006). Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage.J. Neurochem.97582594. 10.1111/j.1471-4159.2006.03780.x

  • 61

    TurskiW. A.CavalheiroE. A.SchwarzM.CzuczwarS. L. J.KleinrokZ.TurskiL. (1983a). Limbic seizures produced by pilocarpine in rats: Behavioural, electroencephalographic and neuropathological study.Behav. Brain Res.9315335.

  • 62

    TurskiW. A.CzuczwarS. J.KleinrokZ.TurskiL. (1983b). Cholinomimetics produce seizures and brain damage in rats.Experientia3914081411.

  • 63

    WangP.MaK.YangL.ZhangG.YeM.WangS.et al (2021). Predicting signaling pathways regulating demyelination in a rat model of lithium-pilocarpine-induced acute epilepsy: A proteomics study.Int. J. Biol. Macromol.19314571470. 10.1016/j.ijbiomac.2021.10.209

  • 64

    WangW.WangW. P.ZhangG. L.WuY. F.XieT.KanM. C.et al (2013). Activation of Nrf2-ARE signal pathway in hippocampus of amygdala kindling rats.Neurosci. Lett.5435863. 10.1016/j.neulet.2013.03.038

  • 65

    WooJ.KwonS. K.KimE. (2009). The NGL family of leucine-rich repeat-containing synaptic adhesion molecules.Mol. Cell. Neurosci.42110.

  • 66

    WuX.ReddyD. S. (2012). Integrins as receptor targets for neurological disorders.Pharmacol. Ther.1346881.

  • 67

    WuX.MuthuchamyM.ReddyD. S. (2016). Atomic force microscopy protocol for measurement of membrane plasticity and extracellular interactions in single neurons in epilepsy.Front. Aging Neurosci.8:88. 10.3389/fnagi.2016.00088

  • 68

    WuX.MuthuchamyM.ReddyD. S. (2017). Atomic force microscopy investigations of fibronectin and α5β1-integrin signaling in neuroplasticity and seizure susceptibility in experimental epilepsy.Epilepsy Res.1387180. 10.1016/j.eplepsyres.2017.10.013

  • 69

    XuJ.WangH.DingK.LuX.LiT.WangJ.et al (2013). Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice.Mediators Inflamm.2013:187873. 10.1155/2013/187873

  • 70

    YalcinkayaC.ErturkO.TuysuzB.YesilG.VerbekeJ. I.KeyserB.et al (2012). A novel GJC2 mutation associated with hypomyelination and Müllerian agenesis syndrome: Coincidence or a new entity?Neuropediatrics43159161. 10.1055/s-0032-1313912

  • 71

    YangJ. W.CzechT.LubecG. (2004). Proteomic profiling of human hippocampus.Electrophoresis2511691174. 10.1002/elps.200305809

  • 72

    ZhangS.ZhuC.LiuQ.WangW. (2005). Effects of chloroquine on GFAP. PCNA and cyclin D1 in hippocampus and cerebral cortex of rats with seizures induced by pentylenetetrazole.J. Huazhong Univ. Sci. Technolog. Med. Sci.25625628. 10.1007/BF02896153

  • 73

    ZhuH.ZhangM.FuY.LongH.XiaoW.FengL.et al (2020). Effects of AQP4 and KCNJ10 gene polymorphisms on drug resistance and seizure susceptibility in Chinese Han patients with focal epilepsy.Neuropsychiatr. Dis. Treat.16119129. 10.2147/NDT.S231352

Summary

Keywords

acute epilepsy, hippocampus, proteomics study, seizures, signaling pathways

Citation

Wang P, Yang L, Yang R, Chen Z, Ren X, Wang F, Jiao Y, Ding Y, Yang F, Sun T and Ma H (2022) Predicted molecules and signaling pathways for regulating seizures in the hippocampus in lithium-pilocarpine induced acute epileptic rats: A proteomics study. Front. Cell. Neurosci. 16:947732. doi: 10.3389/fncel.2022.947732

Received

19 May 2022

Accepted

14 November 2022

Published

01 December 2022

Volume

16 - 2022

Edited by

Marian Christoph Neidert, Kantonsspital St. Gallen, Switzerland

Reviewed by

Imran Imran, Bahauddin Zakariya University, Pakistan; Maryam Ardalan, University of Gothenburg, Sweden

Updates

Copyright

*Correspondence: Peng Wang, Huisheng Ma,

This article was submitted to Non-Neuronal Cells, a section of the journal Frontiers in Cellular Neuroscience

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics